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ABSTRACT 
Christian Michael Parobek: Dissecting the Effects of Selective Pressures on the Genomes of Co-endemic 
Plasmodium vivax and Plasmodium falciparum in Cambodia 
(Under the direction of Jonathan J. Juliano) 
 
 Each year, the malaria parasites Plasmodium vivax and Plasmodium falciparum together infect 
hundreds of millions of people and cause hundreds of thousands of deaths. In Cambodia, these two 
parasites are co-endemic, transmitted by the same vectors, and cause disease in the same populations. 
Recently, pointed efforts have been made in western Cambodia to eliminate malaria. This selective 
pressure provides a natural experiment that enables direct comparison of P. vivax and P. falciparum 
populations. Here, we explore the genetic similarities and differences between co-endemic P. vivax and P. 
falciparum from Cambodia through three questions to be answered. First, we conducted a pilot study in 
which we deep sequenced two important antigens - pvmsp1 and pvcsp - from 48 P. vivax clinical isolates 
and explored the contrasting population genetics of these two antigens. We discovered that, in population 
genetic studies, marker choice has a profound effect on study outcomes, and that P. vivax and P. 
falciparum orthologs can host very different signatures of selection. Next, through whole-genome 
sequencing of 80 P. falciparum isolates, we found that population substructuring associates with 
artemisinin-combination therapy partner-drug in vitro IC50 and with clinical outcomes. This finding 
suggests that the P. falciparum population has in part responded to selective pressures with complex 
demographic changes. Finally, we whole-genome sequenced 70 sympatric P. vivax isolates. We found 
that, in spite of control efforts and in contrast to P. falciparum, the genetic diversity within the P. vivax 
population remains high and has been more rapidly expanding. We identified a minority of orthologous 
loci that have opposite signatures of selection in P. vivax and P. falciparum. Surprisingly, we found  
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evidence of several strong and recent selective sweeps within the P. vivax population at transcriptional 
regulatory loci. This finding suggests that P. vivax may rely on a nuanced response to selective pressure, 
modulating transcript levels as a means to maintain population resilience. 
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CHAPTER 1: THE CLINICAL BURDEN, CAUSES, AND PATHOGENESIS OF MALARIA 
1.1 Epidemiology 
Malaria is a mosquito-borne, parasitic illness that affects hundreds of millions of people each 
year. Although global efforts to eliminate malaria have reduced its burden, in 2015 there were still 214 
million malaria cases (range: 149 - 303 million) and 438,000 deaths (range: 236,000 - 635,000) [1]. Thus, 
despite recent advances in the fight against the disease, malaria is still a leading cause of morbidity and 
mortality throughout much of the world.  
Malaria is a disease of poverty [2]. Of the 106 countries with reported active malaria transmission 
in 2000 [1], nearly all were tropical or subtropical low-income developing countries. Within these 
countries, the most affected individuals are children under five [3] (who are at increased risk prior to 
developing partial immunity), the immunocompromised and pregnant women [4] (as malaria parasites 
find a home in the placenta), and people who spend time outdoors (for example farming or in forested 
areas) (eg. [5,6]). In 2010, malaria cost nearly 70,000,000 disability adjusted life years (DALYs) globally 
[3], and it is estimated that persistent malaria infection during childhood is associated with up to a 50% 
decrease in adult income [7]. Globally, countries with nationwide malaria transmission have 1.6% 
decreased growth in gross domestic product (GDP) than countries with less of a malaria burden [2]. These 
trends likely hold true in Southeast Asia, and specifically in Cambodia, where the present studies take 
place. In 2013, the last year for which there is published data, the Cambodian Ministry of Health and the 
National Malaria Programme reported there were roughly 2000 confirmed malaria cases per month [8], 
with some evidence of recent case-incidence increases [9]. 
1.2 Malaria Biology, Lifecycle, and Host Responses 
Malaria is caused by parasites of the genus Plasmodium. Malaria parasites infect a variety of 
hosts, ranging from reptiles and birds to mammals, primates, and humans. Plasmodium parasites are 
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transmitted by mosquitos of the genus Anopheles, which are ubiquitous throughout the world. Five of 
these Plasmodium species can cause disease in humans: P. falciparum, P. vivax, P. ovale, P. malariae, 
and P. knowlesi. Together, P. falciparum and P. vivax cause the majority of cases globally, with P. 
falciparum being more lethal.  
 All Plasmodium parasites share a similar, and complex, lifecycle. The meiotic and sole diploid 
stage occurs in the Anopheles midgut. After meiosis, haploid sporozoites are produced, which migrate to 
the mosquito salivary glands. While the mosquito draws a bloodmeal from a potential host, sporozoites 
deposit in the host interstitial space, from which they migrate into the bloodstream and infect hepatocytes 
[10]. After several days of intra-hepatic development (variation is species specific), infected hepatocytes 
release schizonts into the bloodstream. Schizonts rupture, each releasing numerous merozoites, which 
infect circulating red blood cells (RBCs). Infected RBCs undergo multiple cycles of parasite replication, 
rupture, and re-infection, causing both a recurring fever and a rapid increase in parasitemia. As a 
byproduct of bloodstage infection, sexual forms, called gametocytes, are produced, which are ingested by 
mosquitoes, repeating the lifecycle. 
With repeated Plasmodium infections, hosts develop partial immunity that may be strain 
transcending; however, absent continued exposure this immunity wanes, though it does not completely 
disappear [11]. Consistent with this, most malaria cases occurring in the United States are among 
travellers returning from visiting friends and relatives who live in malaria endemic settings. Many of 
these travellers formerly lived in malaria endemic settings and presumably had partial immunity to 
malaria, which was lost after immigrating to the United States [12]. Importantly, the correlates of 
immunity to malaria (both P. falciparum-type and P. vivax-type) remain unknown, hindering vaccine 
development.  
1.3 Clinical Characteristics and Treatment 
The clinical manifestations of malaria are caused by blood-stage parasitemia, and are most 
pronounced in children and adults without immunity [13]. Typically, clinical symptoms commence within 
days to weeks of infection, but can manifest more than two months after infection [14]. Malaria can 
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present as uncomplicated or severe. In general, malaria lacks a pathognomonic feature, but rather presents 
as an undifferentiated fever. Patients presenting with uncomplicated disease have a fever that often abates 
and recurs with some periodicity, and can also present with headache, nausea, hepatomegaly, and 
splenomegaly. Severe cases can present with evidence of organ dysfunction including a dramatic anemia 
due to erythrocyte lysis, acute respiratory distress, renal compromise, shock, or neurologic symptoms due 
to sequestration of infected erythrocytes in the cerebral vasculature resulting in severe inflammation.  
Treatment guidelines are species-specific and are determined on a country-by-country basis 
(dictated by each nation’s health ministry or malaria control program). Global and national guidelines are 
frequently updated in response to updated drug resistance profiling. Since 2001, artemisinin-combination 
therapy (ACT) has been the WHO-recommended first-line therapy for P. falciparum. ACT is now also a 
WHO-recommended therapy for P. vivax, and is the preferred treatment for P. vivax in areas of high P. 
vivax chloroquine resistance [15]. The importance of artemisinin for global public health was recently 
recognized when the 2015 Nobel Prize for Medicine was shared by the scientist who isolated artemisinin, 
Tu Youyou. 
1.4 Malaria Prevention 
Beyond treating active malaria cases, prevention strategies are effective at reducing transmission 
and cases [16]. The primary preventative strategies are methods of vector controls, including indoor 
residual spraying (IRS), distribution and use of insecticide-treated bednets (ITNs), mass-screen-and-treat 
or mass-drug-administration campaigns, prophylactic pharmacotherapy in pregnant women, the use of 
transmission-blocking pharmaceutical agents in malaria patients, deployment of malaria village workers, 
and continued efforts to develop an effective vaccine. 
Although the correlates of immunity against P. falciparum and P. vivax are poorly understood, 
pharmaceutical companies, global malaria control efforts, and academic research groups have expended 
vast resources pursuing a malaria vaccine. Malaria vaccines in the general (i.e. non-pregnant) population 
can be grouped into three broad classes: pre-erythrocytic, erythrocytic (also known as “blood-stage”), and 
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transmission-blocking. Two vaccines against the pregnancy-specific P. falciparum antigen var2csa are 
also undergoing active development.  
 Anti-P. falciparum vaccine candidates have progressed further than vaccines against P. vivax, 
with a pre-erythrocytic (CSP-based) [17,18] and an erythrocytic candidate (AMA1-based) [19] having 
completed advanced clinical trials in Africa. Both of these vaccines, however, showed disappointing 
efficacy, due in large part to standing antigenic diversity leading to vaccine escape [19,20]. Novel 
antigens with more constrained genetic diversity have been identified and are now being pursued for 
vaccine development [21,22]. Going forward, longitudinal studies of antibody titers against the entire 
array of potential malaria antigens as immunity develops in children hold great potential for identifying 
and quantifying the antigenic correlates of protection against malaria. Protein microarray and antigen 
phage displays are enabling this work [21,23,24]. 
1.5 Emerging Drug Resistance and Elimination Efforts in Southeast Asia 
In 2009, a significant number of P. falciparum clinical cases with a delayed parasite clearance 
time (PCT) in response to artemisinin treatment were recognized in western Cambodia [25]. The assertion 
that these cases were “artemisinin resistant” (despite the lack of outright treatment failure), spurred a 
debate over the inappropriate use of the term “resistance” [26,27]. Unfortunately, there is now evidence of 
true artemisinin and ACT treatment failures in P. falciparum cases [28]. In some parts of Cambodia, ACT 
failure rates now approach 40% [29]. For simplicity, I will use “artemisinin resistant” and “artemisinin 
resistance” to refer both to cases of delayed clearance and outright failure, unless otherwise specified. 
To neutralize the threat of potential artemisinin resistance, the WHO, with funding support from 
the Gates Foundation, developed the Global Plan for Artemisinin Resistance Containment [30]. The 
stated goal of this ambitious plan was to eliminate artemisinin-resistant drug alleles from western 
Cambodia. In focal areas of artemisinin resistance, it called for increased use of vector-control tools like 
insecticide-treated bednets. It also provided for increased availability of authentic antimalarial 
combination therapies, as well as increased monitoring, including active case detection, focal screen and 
treat programs, mass screen and treat programs, and mass-drug-administration programs. 
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Although this effort reduced the number of P. falciparum cases in western Cambodia, the 
frequency of artemisinin-resistant infections increased [31]. The resistance phenotype has now been 
reported in five countries within the Mekong region [1,32]. Unfortunately, elimination of artemisinin and 
partner-drug resistance is no longer a realistic goal of malaria-control. Rather, control efforts are focused 
on treating with enhanced cocktails of antimalarial drugs, and new efforts are underway to test out new 
treatment regimens in Cambodia. Moreover, there is much discussion regarding the development of new 
pharmacotherapies, and there are a number of new compounds in development [33–35]. 
1.6 The Genetics of Artemisinin and Partner-Drug Resistance 
Despite the early fears of artemisinin-resistant malaria, years passed before a “resistance marker” 
was identified. Early association studies identified several genomic regions that were associated with 
resistance phenotypes, including a portion of chromosome 13 [36,37]. In 2013, a large population-based 
sequencing study identified multiple populations of genetically distinct artemisinin-resistant parasites 
circulating in Cambodia [38], but did not identify a genetic resistance marker. Then, in 2014 Ariey et al. 
found that parasites subjected to continuous artemisinin exposure developed non-synonymous mutations 
in the P. falciparum kelch K13 propeller domain (located on chromosome 13). The authors especially 
noted the presence of a C580Y mutation, and found that this mutation increased in frequency from 2001-
2012 [39]. Follow-up work demonstrated unequivocally that C580Y and other K13-domain mutations do 
confer resistance to artemisinin in vitro [40]. Several mechanisms for P. falciparum kelch K13-mediated 
artemisinin resistance have been proposed. First, it was recognized that mutations in the human homolog 
KEAP1 are implicated as driver mutations in non-small-cell lung cancer [41]. Malaria-specific studies 
have shown associations between P. falciparum kelch mutations and increased phosphatidylinositol-3-
kinase levels [42] and delayed parasite maturation through the intraerythrocytic stage [43].  
A great concern is that artemisinin resistance in P. falciparum will spread to or develop in Africa. 
The fact that there have been multiple independent origins of artemisinin resistance in Southeast Asia [44] 
heightens the urgency of monitoring African P. falciparum clinical isolates for evidence of novel 
artemisinin-resistance markers in kelch or other genes. Collectively, we and others have found that 
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although there is deep genetic diversity at the kelch locus in African isolates, there is no evidence of a 
selective sweep around this locus among African P. falciparum populations [45–47]. This surprising 
finding could be due to (1) the lack of requisite haplotype background that enhances the selective 
advantage conferred by kelch mutations [48] from African isolates, or (2) disadvantageous allele pairings 
that could hinder the transmission of resistance alleles from Southeast Asian isolates to African isolates, 
similar to a mechanism uncovered previously in South American P. falciparum parasites [49]. 
Even as the threat of artemisinin resistance grows, its combination-therapy partner drugs are also 
losing effectiveness due to growing resistance. In Cambodia, increasing failure of artemisinin plus 
mefloquine (MQ) led to the adoption of artemisinin plus piperaquine (PPQ) as front-line therapy in 2012 
[28]. Now, artemisinin/piperaquine combination therapy is also losing its effectiveness [28,50]. Though 
not a closed book, the molecular basis for MQ resistance in P. falciparum parasites is better understood 
than artemisinin. Numerous studies have found that MQ resistance is associated with copy-number 
variations or mutations at drug-resistance transporters [51–53]. Studies are ongoing to identify validated 
PPQ molecular resistance markers. However, in vitro and ex vivo resistance testing of parasites in 
Cambodia has shown dramatic increases in IC50 to piperaquine among parasite isolates. 
1.7 Plasmodium vivax in an Era of Artemisinin Resistance 
Globally, Plasmodium vivax causes at least 80 million cases of malaria each year [54], and, in 
Cambodia, P. vivax accounts for >50% of the total malaria burden [8]. In global guidelines, ACTs are 
now the recommended treatment for P. vivax in areas of chloroquine resistance [15]. In Cambodia, both 
CQ and ART are used for treatment of bloodstage P. vivax, and ACT is becoming the preferred treatment 
as it is now frontline therapy for P. falciparum [29]. Although P. vivax - like P. falciparum - develops 
resistance to antimalarial therapy, there have been no reports of artemisinin-resistant P. vivax clinical 
cases. Additionally, there is no evidence of potentially drug-resistance-causing mutations in the P. vivax 
kelch 13 propeller domain (our unpublished observations and [55]). In addition, although genetic markers 
of chloroquine resistance are present [56], Cambodian P. vivax remains sensitive to that former first-line 
therapy [29]. Despite its sustained and broad sensitivity to pharmacotherapy, P. vivax case incidence has 
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increased in Cambodia, even as P. falciparum cases have fallen dramatically [8]. There is growing 
concern - both in Cambodia and around the world - that the burden of P. vivax malaria is increasing and 
that it will be more difficult to eliminate than P. falciparum malaria. 
1.8 Summary and Questions to be Answered 
Malaria is a widespread and potentially deadly infectious disease caused by Plasmodia spp. 
parasites. Though control efforts in the last decade have dramatically reduced the burden of malaria, it 
still infects hundreds of millions of people a year, and kills hundreds of thousands. Despite these 
advances, there are some concerning trends:  
1. Resistance to first-line combination therapies is becoming more prevalent among P. falciparum 
from Southeast Asia, raising fears that resistance alleles may spread to other parts of the world, 
increasing global malaria-attributable morbidity and mortality. 
2. Even as the incidence of P. falciparum malaria has decreased by >80% in parts of Cambodia, 
cases of P. vivax malaria have increased, raising concerns P. vivax will be more difficult to 
eliminate. 
These trends raise several questions that must be answered to build on the successes of malaria-
elimination programs: 
1. To what extent does next-generation sequencing marker choice affect the conclusions drawn from 
these studies? 
2. What are the selective pressures that shape global genetic diversity at P. vivax antigens, and how 
does this compare with the pressures on P. falciparum orthologs? 
3.  Why is P. vivax more resilient to control measures than P. falciparum, and what are the genetic 
mechanisms of this enhanced resilience? 
4. What are the genetic determinants of ACT partner-drug resistance, and how do partner-drug and 
artemisinin resistance interact? 
5. Why are there multiple co-localized but genetically distinct populations of ACT-resistant P. 
falciparum circulating in Cambodia? 
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CHAPTER 2: DIFFERING PATTERNS OF SELECTION AND GEOSPATIAL GENETIC 
DIVERSITY WITHIN TWO LEADING PLASMODIUM VIVAX CANDIDATE VACCINE 
ANTIGENS
1
 
2.1 Introduction 
Plasmodium vivax causes 80 to 300 million infections per year and over 2.5 billion people remain 
at risk of infection despite malaria elimination efforts [57]. Now, concern over P. vivax is growing due to 
reports of increasingly severe disease [58], emerging chloroquine resistance [59], and multidrug 
resistance [60]. Ultimately, an effective vaccine will be important for controlling P. vivax malaria [61]. 
The fact that humans naturally develop partial immunity to P. vivax and P. falciparum lends hope for 
effective vaccines against these parasites; however, because the majority of global malaria research 
funding targets P. falciparum [54,62], only a handful of P. vivax antigens are currently being considered 
for vaccine development [63]. Among these are P. vivax merozoite surface protein 1 (pvmsp1) and 
circumsporozoite protein (PvCSP). 
PvMSP1, an erythrocytic vaccine candidate, plays an important role in reticulocyte invasion [64]. 
Its C-terminus contains a 42 kDa region, which is processed into 33 and 19 kDa fragments (Figure 2.1A). 
The 33 kDa fragment contains two high-affinity reticulocyte binding clusters (HARBs) (20 kDa and 14 
kDa), and antibodies against the HARBs confer protection in monkeys [65]. In humans, antibodies to the 
42 kDa region have also been associated with clinical protection, making this region an attractive vaccine 
candidate [66–69]. Another vivax protein, PvCSP, is a pre-erythrocytic vaccine candidate and is critical in 
sporozoite motility and hepatocyte invasion [70]. P. vivax circumsporozoite protein has an immunogenic 
central repeat, consisting of two major types of nonapeptide repeats (VK210 and VK247 – there is also a 
                                                     
1
 This chapter originally appeared as an article in the journal PLOS Neglected Tropical Diseases. The original 
citation is as follows: Parobek CM, Bailey JA, Hathaway NJ, Socheat D, Rogers WO, Juliano JJ. “Differing Patterns 
of Selection and Geospatial Genetic Diversity within Two Leading Plasmodium vivax Candidate Vaccine Antigens,” 
PLOS Neglected Tropical Diseases 8, no. 4 (April 2014): e2796. 
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rarer repeat type termed vivax-like) flanked by highly conserved 59 and 39 regions (Figure 2.1B). The P. 
falciparum ortholog of pvcsp, as formulated in RTS,S, is the most advanced P. falciparum vaccine 
candidate to date, showing modest efficacy at one year interim analysis in a Phase III trial [17]. 
Despite this knowledge of pvmsp1 and PvCSP, little is known about the geospatial genetic 
diversity of these antigens. Variation in these antigens may become a mechanism of vaccine resistance if 
strain-specific immunity is important for protection, as has been seen in some P. falciparum vaccine 
candidates [71]. Vaccine trials of P. falciparum AMA1 and MSP2 as well as genetic crosses using P. 
chabaudi underscore the importance of strain-specific immunity as a determinant of outcome [19,72–74]. 
Additionally, despite initial evidence that strain-specific immunity may not impact RTS,S efficacy [75–
77], the incomplete protection afforded by the RTS,S vaccine in Phase II and III trials [17,78,79] has 
prompted a careful examination of strain-specific responses to this vaccine. Thus, as momentum grows 
for field trials of P. vivax vaccine antigens, carefully designed population genetic studies of P. vivax 
vaccine candidates will be key to assess the need for multivalent vaccine formulations. 
To better understand the selective forces on, and geospatial genetic diversity associated with 
pvmsp1 and pvcsp, we used the Illumina sequencing platform to determine haplotypes for 42 kDa region 
of pvmsp1 (n=44) and we used the PacBio and Illumina platforms to sequence the complete pvcsp gene 
(n=47) from Cambodian isolates [80]. To dissect the immune selection acting on these regions, we 
studied these sequences using population genetic tests of selection and models of tandem repeat 
evolution. To evaluate the global genetic diversity of pvmsp1 and pvcsp, we extracted worldwide pvmsp1 
and pvcsp sequence data available in GenBank (n=238 for pvmsp1 and n=412 for pvcsp) (Figure 2.2), 
and studied our sequence data alongside the sequences from GenBank. Finally, we compare the 
performance of Illumina and PacBio sequencing to traditional Sanger sequencing, and discuss the 
potential and challenges of next-generation sequencing for population genetic studies of malaria parasite 
antigens. 
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2.2 Materials and Methods 
2.2.1 Parasite isolates 
Clinical samples from a previous study were used for this study [81]. Written informed consent was 
acquired from each individual and the study was approved by the IRB at University of North Carolina, the 
IRB of the Naval Medical Research Unit #2, Jakarta, Indonesia, and the Cambodian National Ethical 
Committee for Health Research. Briefly, blood spots were collected from 109 patients with 
uncomplicated P. vivax malaria, presenting to a clinic in Chumkiri, Cambodia during 2006–07. We 
selected 48 subjects with a multiplicity of infection (MOI) of one (n=20) or two (n=28) for sequencing. 
MOI was determined by heteroduplex tracking assay (HTA) [80,82]. Briefly, in an HTA, radiolabeled 
DNA probes are annealed to genomic DNA and drawn through a non-denaturing gel matrix. The number 
of bands observed represents the number of conformational differences present among heteroduplexes, 
and is a proxy for the number of infection clones (MOI). Details of the method have been published 
elsewhere [83]. 
2.2.2 Amplification of pvmsp1 and pvcsp 
The pvmsp1 42 kDa region (nucleotides 3973–5239 of Sal1 PVX_099980, www.PlasmoDB.org) 
was amplified using primers F: 5’-CAG GAC TAC GCC GAG GAC TA-3’ and R: 5’-GGA GGA AAA 
GCA ACA TGA GC-3’ and an Eppendorf Mastercycler (Eppendorf, Hauppauge, NY) in 50 mL reactions 
containing 5 µL 10x Qiagen Hotstar Master Mix (Qiagen, Valencia, CA), 0.25 µL Qiagen Hotstar Taq, 
300 nM forward primer, 300 nM reverse primer, 1 µL 10 mM dNTPs, and 5 µL 5–10 mM template. 
Cycling conditions were: 95℃ x 15m; 35 cycles of 95℃ x 45s, 55℃ x 45s, 72℃ x 3m; and 72℃ x 10m. 
The pvcsp gene (PVX_119355) was performed by nested PCR. The outer step used primers F: 5’-GGC 
AAA CTC ACA AAC ATC CA-3’ and R: 5’-TGC GTA AGC GCA TAA TGT GT-3’. Reactions were as 
above except for 600 nM forward primer, 600 nM reverse primer, 1 µL 10 mM dNTPs, 5 µL 5–10 mM 
template, 6 µL of 25 mM MgCl2 , and 28.75 µL H2O. Cycling conditions were: 95℃ x 15m; 25 cycles of 
95℃ x 45s, 45℃ x 45s, 72℃ x 3m; and 72℃ x 10m. The inner step used 600 nM of each of the primers F: 
5’-AAA CAG CCA AAG GCC TAC AA-3’ and R: 5’-GAC GCC GAA AAT ATT GGA TG-3’ using 5–
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10 µL of the initial amplification. The cycling conditions were: 95℃ x 15m; 25 cycles of 95℃ x 45s, 54℃ 
x 45s, 72℃ x 3m; and 72℃ x 10m. 
2.2.3 Amplicon sequencing and sequence determination 
pvmsp1 and pvcsp amplicons were fragmented by acoustic shearing (Covaris, Woburn, MA) 
using the following settings: 10% duty cycle, 5.0 intensity, 200 cycles per burst, and frequency sweeping 
mode. Forty-eight barcoded libraries were prepared using the NEXTflex multiplex library kit (Bioo 
Scientific, Austin, Texas), each containing the pooled pvmsp1 and pvcsp amplicons from one patient. 
Libraries were sequenced on the Illumina HiSeq2000, using the paired-end 100 base pair chemistry 
(Illumina, San Diego, CA). We used Lasergene SeqMan NGen v.3.1.1 (DNASTAR, Madison, WI) to 
assemble pvmsp1 short reads de novo and to determine SNP frequency within each assembly. For 
purposes of comparison and confirmation, we re-sequenced 9 pvmsp1 amplicons with differing MAFs: 3 
samples with all MAFs>90%; 3 samples with all MAFs between 60% and 90%; 3 samples with 
MAF<60% for at least one SNP. Sanger-sequence haplotypes were compared to predicted Illumina 
haplotypes. Based on these comparisons, only predicted pvmsp1 haplotypes with MAF>60% at all 
polymorphic sites were used in our analysis. In addition to Illumina sequencing, pvcsp amplicons were 
sequenced using PacBio Circular Consensus Sequencing (Pacific Biosciences, Menlo Park, CA). One 
PacBio SMRT cell produced a total of 12,103 reads with a minimum of 36 circular consensus coverage, 
which were used for this study. These were further filtered, removing truncated reads or reads with errors 
in the barcode. This left 8430 reads (3979 forward and 4451 reverse). Clustering attempted to minimize 
false positive haplotypes due to erroneous base calls and PCR slippage within the tandem repeat region. 
For each sample, haplotypes were created by clustering reads, allowing reads differing only by indels of 1 
and 2 bases and low quality mismatches to collapse. Low quality was defined as either a mismatching 
base Q<30 or any Q<25 within an 11 basepair region centered on the mismatch, as has been applied 
previously to rigorous SNP discovery from shotgun data [84]. To overcome artifacts of PCR infidelity 
due to slippage events leading to shortened repeats and false haplotypes, we set a high threshold requiring 
that co-occurring haplotypes of the same repeat type beat high frequency in order to exclude the low 
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frequency  variation/stuttering in the repeat region. Haplotype repeat type was then determined by 
translation and the most frequent haplotype of each major repeat type (VK210 and VK247) present was 
kept >0.5%. Additional haplotypes of major repeat types were kept if they were common (>20%) and 
thus unlikely to be due simply to low frequency slippage events. In total, across all samples, 4081 of the 
8430 reads clustered contributed to utilized haplotypes.  
The long-read haplotypes determined through consensus clustering were used as templates for 
short-read alignment using Bowtie2 v2.1.0 [85], with very-sensitive alignment parameters and stringent 
filtering for Mapping Quality Score and Alignment Score. Final sequence predictions were used for the 
analyses in this paper and were deposited in GenBank under accession numbers JX461243-JX461285 and 
KJ173797- KJ173802 for pvcsp, and JX461286-JX461333 for pvmsp1. 
Rarefaction curves of haplotypes were calculated using EstimateS v9.0. Individual-based curves 
using sampling without replacement were estimated [86] and extrapolated to 2x the actual sample number 
[87]. Rarefaction plots were visualized in the R base package (http://cran.us.r-project.org/). 
2.2.4 Acquisition of published sequences for inter-population comparisons 
GenBank was queried for population sets published prior to August 1, 2013, which included 
sequence data for the 42 kDa region of pvmsp1 and the whole-gene of pvcsp. Sequences from a recent 
publication [88] were excluded because the isolates were collected over the course of a 12 year period. 
The authors provide evidence that the haplotype distribution of this population changed substantially over 
time, making this population inappropriate for our analysis of selection. 
2.2.5 Assessing selection on pvmsp1 and pvcsp 
Population datasets with >25 sequences that were collected over a span of ≤4 years were included 
for analysis of selection. We used DnaSP v5.1 to perform tests of selection [89]. We calculated 
polymorphism and Tajima’s D across pvmsp1 and the pvcsp constant regions using a 50 bp sliding 
window with a 25 bp step size. We also performed 1000 coalescent simulations with recombination to 
determine a 95% confidence interval and centile for each Tajima’s D estimate [90]. To test for long-term 
selection, we used the McDonald-Kreitman (MK) test [91]. Skew was calculated using Fisher’s exact test 
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(two tailed). For the pvmsp1 42 kDa region amplicons reported here and by others, 15 Plasmodium 
knowlesi pkmsp1 isolates from Thailand [92] (accession numbers JF837339-JF837353) were used as the 
interspecies outgroup. Three insertions and deletions occurred in the 42 kDa region of pvmsp1 relative to 
pkmsp1, and were not considered. We could not obtain MK estimates for pvcsp sequences due to 
numerous insertions and deletions relative to pkcsp. For analysis of pvcsp repeats, we performed pairwise 
comparisons of untranslated repeat units within individual pvcsp sequences [93]. We calculated skewness 
and mean nucleotide differences between repeat units, as previously reported [94]. Similar to the methods 
of Dias et al., 2013, we also calculated dN/dS on the first 1–459 bases of all 32 VK210 repeat regions and 
the first 1–540 bases of all 15 VK247 repeat regions. This analysis was performed in MEGA5, using the 
Nei-Gojobori method [95]. 
2.2.6 Phylogenetics and statistics to determine population structure 
Interpopulation heterogeneity was first assessed using Wright’s fixation index (FST). Pairwise 
fixation values between pvmsp1 populations were calculated in DnaSP. Site-specific fixation values for 
pairwise comparisons among Cambodia, NW Thailand, S Thailand, India, and Turkey were generated 
using the analysis of molecular variance (AMOVA) function within Arlequin v3.11 [96].  
Neighbor-joining trees for pvmsp1, pvcsp VK210, and pvcsp VK247 were drawn using the ape 
package for R [97]. To generate trees based off pvmsp1, distance calculations between haplotypes were 
performed in MEGA5 using the maximum composite likelihood method to construct a neighbor-joining 
tree file. For the pvcsp CR, we used MS_Align (v.2.0) [98,99] to create genetic distance matrices 
separately comparing both the VK210 and VK247 repeat arrays. MS_Align generates an event-based 
genetic distance using a model of tandem repeat evolution (expansion, deletion, substitution). Cost 
parameters for MS_Align were set to 0.1 for amplification or contraction and 5 for repeat insertion or 
deletion. A pairwise cost table of repeat-to-repeat mutations was created in MEGA5 using the maximum 
composite likelihood method and used as input for MS_Align [93,100]. MS_Align output matrices were 
used by FastME [101,102] to construct neighbor-joining trees with balanced branch-length estimation. To 
cluster geographic groups, we calculated Hudson’s nearest-neighbor statistic (SNN) [103]. Input was in the 
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form of a pairwise distance matrix between all haplotypes for each phylogeny. For this statistic, highly 
distant populations have values approaching 1 while panmictic populations have values near 0.5. To test 
the reproducibility of the geographic clustering predicted by SNN, 1000 jackknife samplings were 
constructed for both pvmsp1 and pvcsp VK210 and VK247 populations using Fast UniFrac [104]. For 
each jackknife replicate, 5 individuals, based on the size of the smallest population, were randomly 
selected from each population and used to redraw trees. Observed splits between geographic populations 
were quantified and used to assign confidence to predicted geographic clusters. To evaluate potential 
mutational paths connecting all pvmsp1 haplotypes, we constructed a median-joining network using 
NETWORK v4.6 (Fluxus Engineering, Suffolk, England) [105]. This method expresses multiple plausible 
evolutionary paths in the form of cycles. A similar analysis was not completed for pvcsp due to the 
variable length of CR haplotypes. 
2.3 Results 
2.3.1 pvmsp1 sequences 
We Illumina sequenced pvmsp1 42 kDa-fragments (Figure 2.1A) from 48 patients, and compared 
these to Sanger sequencing data for selected samples. Illumina haplotypes with a major allele frequency 
of >60% agreed with Sanger haplotypes in every case tested (n=6). Illumina haplotypes with a major 
allele frequency of <60% did not consistently agree with Sanger haplotypes (n=3). Thus, we were able to 
build 44 complete pvmsp1 42 kDa haplotypes (26 unique haplotypes) with a major allele frequency of 
>60% at all polymorphic sites (Table 2.1). The average coverage depth for all isolates was >800 reads per 
base, with all bases having ≥100 reads of coverage. Haplotype accumulation (rarefaction) curves were 
estimated, and then further extrapolated to show that our sample captured fewer than half the total pvmsp1 
haplotypes in this region of Cambodia (Figure 2.3). In addition to these isolates, we identified 238 
submissions in GenBank [106–110] (Table 2.2) containing either the whole-gene or 42 kDa-region 
sequence information. 
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2.3.2 Detecting signatures of selection within pvmsp1 
The interaction between human host and the parasite has had a profound impact on the parasite 
genome, leaving behind characteristic ‘‘signatures’’ of natural selection [111], which are detectable using 
population genetics approaches to examine sequence diversity. We first assessed nucleotide diversity 
(Figure 2.4A), and observed a spike of polymorphism in the region between the two HARBs (positions 
4348–4731 in the Sal1 reference). We termed this the ‘‘intervening region’’. To test whether the diversity 
in the intervening region is due to long-term selection, we used the McDonald-Kreitman (MK) test [91] to 
compare the ratio of non-synonymous to synonymous nucleotide polymorphisms between the Cambodian 
P. vivax population and a Thai P. knowlesi population [92]. We observed a highly elevated MK ratio 
(p=0.00427) in the intervening region but not in the HARBs (data not shown) or the entire 42 kDa region 
(p=0.681), suggesting that the intervening region is under long-term selective pressure (Table 2.3). To 
determine whether the long-term selective pressure shaping the intervening region is potentially due to 
human immunity, we assessed balancing selection in this region, as balancing selection within a malaria 
antigen suggests that the antigen is a target of the human immune system [111]. We applied Tajima’s D 
test of neutrality [112] to five geographically distinct P. vivax populations (all populations with n>25, 
accounting for 190 of 238 available sequences) (Table 2.1, Figure 2.4B). In panmictic populations with 
an uncomplicated demographic history [111], the Tajima’s D statistic can indicate whether a nucleotide 
sequence is under directional (D<0) or balancing selection (D>0). Populations not subjected to recent 
bottlenecks (i.e. Cambodia, India, and NW Thailand, [106,110]) demonstrated a significant signature of 
balancing selection in the pvmsp1 42 kDa region (Table 2.1). This signature occurred specifically in the 
intervening region (Figure 2.3B), and is consistent with the conclusion that human immunity targets the 
intervening region. The three regions of the pvmsp1 fragment that are considered vaccine candidates were 
each assessed for diversity in the Cambodian population [64,113]. In contrast to the intervening region, 
the 20 kDa HARB (Sal1 positions 4021–4347) and 14 kDa HARB (Sal1 positions 4732–4941) showed no 
coding polymorphisms and no evidence of balancing selection, similar to recent reports [113]. The 19 
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kDa fragment (Sal1 nucleotide positions 4918–5239) also showed limited diversity, with only a K1709E 
substitution, and no evidence of balancing selection. 
2.3.3 Geospatial genetic diversity at the pvmsp1 42 kDa region 
Although the pvmsp1 42 kDa region contains potential vaccine candidates [64,113], the 42 kD 
region’s global genetic diversity has not been carefully evaluated. To study pvmsp1 42 kDa diversity, we 
calculated Wright’s Fixation index (FST) [114] for each pairwise comparison between five diverse 
populations (Table 2.4). FST values between naturally evolving parasite populations (Cambodia, NW 
Thailand, and India) approached zero, showing a high degree of genetic similarity, while comparisons 
with populations that have undergone a recent bottleneck (S Thailand and Turkey) showed a high degree 
of genetic distance due to their limited number of haplotypes. Similarly, FST values calculated for each 
variable site demonstrate a high degree of homogeneity in pairwise comparisons between the Cambodia, 
NW Thailand, and India populations across all sites, and substantial heterogeneity between S Thailand 
and Turkey across all sites (Figure 2.5). This is evidence that balancing selection maintains a similar 
range of alleles in the pvmsp1 42 kDa region of multiple geographically diverse naturally evolving P. 
vivax populations. To visualize whether 42 kDa sequences cluster according to geography, we compared 
all unique haplotypes in a single neighbor-joining tree, which revealed little clustering according to 
geographic origin (Figure 2.6). We quantified the extent of this clustering using Hudson’s nearest-
neighbor statistic (SNN), which assesses how frequently a variant’s nearest neighbor is from the same 
population [103]. In both global and pairwise comparisons, pvmsp1 42 kDa sequences from naturally 
evolving populations in Cambodia, India, and NW Thailand showed no evidence of strong geographic 
clustering (Table 2.5). To further confirm this finding, a neighbor-joining consensus tree was created and 
underwent 1000 jackknifed replicates (Figure 2.7A). Results showed that the predicted splits between 
most populations occurred only less than 50% of the time, providing strong evidence that there is minimal 
geographic clustering of pvmsp1 42 kDa sequences. To better understand the evolutionary relationships 
between pvmsp1 haplotypes from around the world, we employed a median-joining network to describe 
the set of potential mutational paths between all available global pvmsp1 42 kDa sequences [105]. The 
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network shows extensive admixture of parasite populations from diverse locales, with numerous 
mutational paths connecting haplotypes (Figure 2.8). With the exception of populations from S Thailand 
and Turkey, which have undergone recent bottlenecks, these data provide further evidence that there is no 
clustering by geography. 
2.3.4 pvcsp sequences 
We sequenced the complete pvcsp gene from 43 isolates using the PacBio and Illumina platforms. 
De novo assembly of the Illumina paired-end short reads was not possible, due to over-collapse in the 
central repeat (CR) region, resulting in inappropriately short CRs. In contrast, PacBio long reads allowed 
the gene to be sequenced in its entirety and, after clustering, predicted 47 pvcsp haplotypes within the 43 
samples. Reported error rates for PacBio sequencing have been high, especially for indels [115]; however, 
the use of Circular Consensus Sequencing allows single DNA fragments to be read multiple times, 
decreasing the error rate of the final predicted sequence. To check the accuracy of PacBio haplotypes, 
individual haplotypes were used as a template for alignment of Illumina reads from the same clinical 
isolate. The addition of Illumina reads corrected only a single 1-bp deletion in a single haplotype. 
Therefore, after clustering, PacBio-predicted haplotypes have an error rate of 1/(~1200 
basepairs/sequence x 47 sequences), or approximately 0.002%. 
Considering the entire gene, there were 24 unique haplotypes at the nucleotide level, and most 
genetic diversity was within the CR (Figure 2.1). Both nonapeptide repeat array types - VK210 (total 
n=32, range 17-21 repeat units) and VK247 (total n=15, range 20-21 repeat units) – were represented in 
our Cambodian population, with no VK210–VK247 hybrids (reviewed in [116]). The average Illumina 
short-read depth for each isolate was >1000, with all bases having ~5 reads of coverage. In addition to our 
isolates, we identified one cohort of nearly complete pvcsp sequences (n=27), and 12 cohorts of CR 
sequences (n=385) [117–122] (Table 2.1). An extrapolated rarefaction curve showed that we sampled 
more than two thirds of the pvcsp CR haplotypes in this part of Cambodia, and that there are significantly 
fewer pvcsp CR variants in this region of Cambodia than pvmsp1 42 kDa variants (Figure 2.3).  
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2.3.5 Detecting signatures of selection within pvcsp  
In contrast to pvmsp1, the 5’ and 3’ non-repeat regions of pvcsp had no significant signatures of 
selection either by the MK test (data not shown) or Tajima’s D test (Table 2.1). The 5’ non-repeat region 
in the Cambodian cohort showed a non-significant signature of balancing selection (Table 2.1 and Figure 
2.3D), which was due to a G38N amino acid polymorphism. This polymorphism also was observed in 
6/16 parasites from the Latin Pacific region (JQ511263-JQ511276, JQ511279, JQ511286) and 2/27 
parasites from Colombia (GU339072 and GU339085). The 39 non-repeat region had little evidence of 
balancing selection, with Tajima’s D values <0 (Table 2.1 and Figure 2.4D). Within pvcsp, an 18 amino-
acid C-terminal motif known as Region II (amino acid residues 311–328 in Sal1) is important for parasite 
invasion of hepatocytes [123] and purportedly contains both B and T-cell epitopes [124,125]. Among all 
Cambodia and Colombia parasite isolates, this motif is completely conserved at the nucleotide and protein 
level, with an amino-acid sequence of EWTPCS VTCGVGVRVRRR, similar to previous reports [113]. 
To better understand the selective forces acting upon the pvcsp CR, we assessed the dN/dS ratio 
for Cambodian VK210 and VK247 [118]. Strikingly, synonymous substitutions were strongly favored in 
both VK210 (dN/dS = 0.267; Z test p<0.001) and VK247 (dN/dS = 0.166; Z test p<0.001) repeats. This is 
consistent with the finding that VK210 and VK247 isolates from around the world consistently 
demonstrate a depressed dN/dS ratio, suggesting that the VK210 and VK247 repeat regions are both 
under strong purifying selection [118]. The CR of P. falciparum csp is thought to evolve by slipped-
strand mispairing [94]. To understand if a similar mechanism works in the pvcsp repeats, we studied the 
mismatch distribution of pairwise genetic distances between untranslated repeat units within each VK210 
and VK247 repeat array type in Cambodia. Consistent with another study [120], we observed a strong 
right skew in the proportion of genetic differences between pairwise VK210 repeat comparisons, and 
between pairwise VK247 repeat comparisons, evidence that pvcsp repeats have a high proportion of 
identical or nearly identical repeats (data not shown). This finding is consistent with a continuous and 
rapid expansion and contraction of repeats by slipped-strand mispairing, which may be a mechanism to 
evade host immunity [94]. 
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2.3.6 Geospatial genetic diversity at the pvcsp central repeat 
A recent study assessed global genetic diversity in the pvcsp CR, but did not define the correlates 
of differentiation between populations [118]. Moreover, this report investigated CR diversity by using a 
subset of the repeat region that was invariant in length. This approach may not reflect true population 
structure as it only assesses repeats early in the CR. Indeed, we have found that certain repeat types do 
cluster in locations within the repeat arrays (data not shown). To more rigorously study the global 
diversity of the pvcsp CR, we modeled CR repeat expansion, contraction, and substitution using 
MS_Align, which calculates an event-based genetic distance between CR haplotypes [98]. From these 
data, we constructed neighbor-joining trees for global VK210 and VK247 repeat arrays isolates (Figure 
2.9 and Figure 2.10). In contrast to pvmsp1, the VK210 and VK247 trees revealed striking geographic 
clustering by country and continent. We quantified clustering using Hudson’s SNN, and observed strong 
genetic differentiation between most geographically diverse parasite populations, in contrast to pvmsp1 
(Table 2.5). To confirm this finding, neighbor-joining consensus trees for both VK210 and VK247 were 
subjected to 1000 jackknife replicates and the reproducibility of predicted splits between populations was 
tested demonstrating a strong correlation between genetic distance and geography (Figure 2.7B–C). 
We were able to define the peptide sequence basis of the clustering observed among pvcsp CR 
repeats. For VK210 repeats, almost all (81/84) Latin American repeat arrays contained either a 59 
(GDRADGQPA) 4 or an internal (GDRADGQPA) 3–4, while very few (11/278) of the Asian sequences 
contained one or both of these features. Similarly, for VK247 repeat arrays, all (34/34) Latin American 
sequences began with a single EDGAGDQPG repeat, while only one (1/44) Asian sequence began with 
this repeat. These sequence features may represent a reliable method to assign sequences to a geographic 
region. 
2.4 Discussion 
This study (1) presents the first population set of pvmsp1 and pvcsp sequences from Cambodia, 
(2) identifies a signature of putative immune-mediated, frequency-dependent selection in the pvmsp1 42 
kDa region and the pvcsp CR, and (3) provides the most comprehensive evaluation to date of geospatial 
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genetic diversity for these genes. We also demonstrate the feasibility of using a next-generation 
sequencing approach to study the genetic diversity of malaria antigens. 
A distinguishing feature of this study is the use of next-generation sequencing methods to 
generate P. vivax amplicon sequence data from clinical isolates. This work represents a first step into this 
largely unexplored territory. As a relatively new technology, next-generation sequencing methods must be 
validated before use in molecular epidemiological studies. We provide evidence that the dominant 
Illumina-predicted pvmsp1 haplotypes are consistent with Sanger sequencing, and are fit for comparison 
with population sets generated by traditional sequencing methods. Methods for predicting multiple 
haplotypes from short-read sequencing are under development and will need further validation. We also 
demonstrate the ability of combined PacBio-Illumina haplotypes to predict pvcsp VK210 and VK247 
haplotypes out of individual mixed infections. As next-generation sequencing methods are utilized more 
frequently for population genetic studies of infectious diseases, the methods introduced here will be 
further improved and will help to provide greater insight into Plasmodia population genetics. 
2.4.1 Evidence of selection in both pvmsp1 and pvcsp 
We found compelling genetic evidence that the pvmsp1 42 kDa intervening region is under strong 
immune pressure in multiple panmictic populations. Results from the MK test suggested that this region 
is under sustained selective pressure (Table 3); however, because a positive MK test can signify balancing 
selection or weak negative selection [126,127], we tested the hypothesis that this region is under 
balancing selection using Tajima’s D test of neutrality. Since multiple populations showed strong 
evidence of balancing selection by Tajima’s D (Table 2.1, Figure 2.4B), we conclude that the intervening 
region is undergoing continual diversifying, balancing selection. An alternative hypothesis is that the 
positive Tajima’s D values are an artifact of recent population contractions. Because (1) a positive 
Tajima’s D was observed in multiple populations, and (2) other regions of pvmsp1 contained negative 
Tajima’s D values, we conclude that the 42 kDa intervening region of pvmsp1 undergoes frequency-
dependent (and likely immune-mediated) balancing selection. 
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Because pvmsp1 is a merozoite surface antigen, it is highly accessible to antibodies and 
complement. The predicted structure of the 42 kDa region shows that the 33 kDa fragment covers the 19 
kDa fragment [66,128], limiting its exposure to the human immune system relative to the 33 kDa 
fragment. This observation could explain the extensive balancing selection present in the 33 kDa 
fragment (specifically, the intervening region) but not in the 19 kDa fragment. Additionally, this finding 
suggests that the sliding window approach for evaluating polymorphism and balancing selection may help 
generate hypotheses about functionally important (19 kDa fragment, for example) or immunologically 
dominant (the intervening region, for example) regions of P. vivax proteins.  
For pvmsp1, Tajima’s D and FST were inversely correlated. Populations with strong evidence of 
high Tajima’s D in the pvmsp1 intervening region showed a low genetic differentiation by FST. This 
suggests that in naturally evolving populations, diversification of this region is extensive and maintains a 
similar range of genetic diversity despite geographic distance. Populations that have undergone a recent 
bottleneck show a low Tajima’s D with relatively few variants and strong genetic differentiation from 
more diverse populations. This suggests that if strain-specific immune responses are important in vaccine 
efficacy, vaccines may work more effectively if other interventions can be used to bottleneck the 
population, thus decreasing its genetic diversity [106].  
The central repeat region (CR) is a primary immunodominant region of PvCSP. Though 
alignment-based methods to assess for selection (Tajima’s D, for example) cannot be employed in a 
tandem repeat region, there is wide-ranging evidence that selective pressures shape the genetic 
composition of the pvcsp CR [129–133], including new evidence hinting that hosts develop strain-specific 
immunity to P. falciparum NANP repeats of varying lengths [134]. Indeed, the presence of two distinct 
repeat types (VK210 and VK247) may itself be evidence of selection as suggested in a study of the P. 
cynomolgi csp CR [132].  
Our analysis of the two CR array types, VK210 and VK247, also suggests that selection is 
occurring in this region. In pairwise comparisons of nucleotide and amino acid differences, we observed a 
positive skew showing decreased differences among repeat units. This finding is consistent with Patil et 
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al.’s study of pvcsp isolates from Brazil [120,135], and provides further evidence that both VK210 and 
VK247 repeat arrays may continuously evolve via slipped-strand mispairing [94]. Furthermore, consistent 
with a recent study of selection in worldwide pvcsp isolates [118], we found that Cambodian pvcsp 
VK210 and VK247 isolates have a strong bias toward synonymous substitutions. This signature of 
purifying selection is consistent with reports from pfcsp [136–138] and suggests that there are a limited 
number of amino acid polymorphisms allowable within this repeat region. Taken together, these findings 
suggest that expansion, contraction, and rearrangement of repeat units, rather than generation of novel 
repeat units through mutation, maintain genetic diversity at the pvcsp locus in both VK210 and VK247 
variants. This phenomenon may be responsible for immune evasion [120,135].  
Although these two P. vivax genes are orthologs of well-characterized vaccine candidate antigens 
from P. falciparum malaria, substantial differences are seen in the effects of immune selection between 
these genes and their orthologs. Previous reports have shown that the functionally similar pfmsp1 42 kDa 
fragment has relatively low nucleotide diversity and lacks evidence of balancing selection by Tajima’s D 
[139]. P. falciparum csp, on the other hand, shows a high level of nucleotide diversity [140–142] and 
modest Tajima’s D elevations in the C-terminal T cell epitopes [140,143]. These patterns are in stark 
contrast to our observations in P. vivax, and this highlights the need for P. vivax-specific studies to 
determine appropriate candidate vaccine antigens.  
Finally, our analysis of the pvmsp1 42 kDa region underscores the importance of selecting an 
appropriate parasite population for population-genetic studies. We did not observe signatures of balancing 
selection in pvmsp1 populations from S Thailand or Turkey. This is likely due to bottlenecks secondary to 
robust malaria control measures employed in S Thailand [106] and limited human migration in Turkey 
[110]. Thus, appropriate selection of panmictic populations for these studies is critical. 
2.4.2 Differing patterns of geospatial genetic diversity at pvmsp1 and pvcsp 
Using both tree-based and statistical methods [144], we found that pvcsp, but not pvmsp1, showed 
strong clustering by geography (Tables 2.4-2.5, and Figures 2.6–2.10). For pvmsp1, we observed little 
geographic clustering among naturally evolving parasite populations, suggesting that immune selection 
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maintains similar pvmsp1 alleles around the globe. Notably similar findings have been described in Duffy 
Binding Protein and Thrombospondin-related anonymous protein in P. vivax malaria [113], while a recent 
global survey of diversity in the Apical Membrane Antigen 1 found evidence of geographically restricted 
haplotypes [145]. In contrast to pvmsp1, we found that pvcsp variants demonstrate strong evidence of 
geographic clustering. This juxtaposition between pvmsp1 and pvcsp sequences is similar to what has 
previously been described for merozoite and sporozoite antigens in P. falciparum [146]. The population 
sets included in this survey were collected in different years. While it is known that novel P. vivax surface 
antigen types can appear in the course of a decade [109], it is difficult to 
assess the magnitude of this effect on our analyses. As more pvmsp1 and pvcsp population sets are 
collected, this will become clearer. 
It is interesting that the CR of pvcsp shows evidence of multiple forms of selection: (1) the 
depressed number of non-synonymous mutations suggests purifying selection, (2) the differences in CR 
genotypes between geographic locations suggests directional selection, and (3) the genetic composition of 
the repeats suggests rapid expansion and contraction, possibly due to immune selection. It is unclear what 
drives the first two signatures of selection. We hypothesize a model in which purifying selection within a 
population limits the amino acid composition of repeats due to functional constraints of the protein, while 
directional selection between populations is driven by environmental factors.  
One environmental factor that may explain both the purifying and directional selection of parasite 
pvcsp CR sequences is the mosquito vector. The circumsporozoite protein is expressed in the mosquito 
during oocyst development [147] and in the salivary glands [148,149]. It is also critical in sporozoite 
motility [70]. We found no overlap in the distribution of Anopheline species between the countries from 
Asia and Latin America included in this study (data not shown) [150–152]. Furthermore, there is 
substantial evidence that different Anopheline species and strains show differential ability to be infected 
by malaria [153–156]. 
Regardless of the cause of the differing patterns of geospatial genetic diversity we observed in 
pvmsp1 and pvcsp, the observation itself has significance for vaccine design. The malaria vaccine field is 
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just beginning to unravel how antigenic diversity within a single parasite population can reduce vaccine 
efficacy [157]. Our findings highlight an additional level of complexity that will hinder the 
implementation of a P. vivax vaccine – antigenic variability. While the effects of immune cross-reactivity 
against different antigenic variants aren’t fully known, the extensive intrapopulation variability seen in 
pvmsp1 may necessitate a highly multivalent pvmsp1 vaccine, while the dramatic interpopulation 
variability seen in pvcsp suggests that a PvCSP-based vaccine that is effective in one part of the globe 
may not be effective in other regions. Thus, a thorough understanding of the geospatial genetic diversity 
of candidate vaccine antigens must inform antigen selection for vaccine design. 
2.4.3 Data Availability 
The pvcsp sequences generated through this work are deposited at GenBank under accession numbers 
JX461243-JX461285 and KJ173797-KJ173802. The pvmsp1 sequences generated through this work are 
deposited at GenBank under accession numbers JX461286-JX461333. 
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pvmsp1: 42 kDa region 
Cambodia 44 62 24.8 0.020 26 0.950 2.08
1
 
India 28 64 24.9 0.021 27 0.997 1.32
1
 
NW Thailand 65 62 24.9 0.020 34 0.968 2.42
1
 
S Thailand 67 42 6.46 0.005 5 0.336 -0.986 
Turkey 30 33 8.33 0.007 3 0.536 -0.001 
pvcsp: N- and C-terminal domains 
Cambodia 47 - - - 24 - - 
N-terminal non-repeat 3 0.971 0.003 3 0.500 0.901 
C-terminal non-repeat 2 0.318 0.001 2 0.159 -0.538 
Columbia 27 - - - 27 - - 
N-terminal non-repeat 2 0.285 0.001 2 0.143 -0.954 
C-terminal non-repeat 0 - - 1 0.000 - 
 
Table 2.1 Summary population genetic data for Plasmodium vivax antigens. 
This table includes all population sequence sets which contained sufficient numbers to perform allele-
based tests of neutrality. Population sets which included sequence data only for pvcsp repeat regions alone 
are not summarized here. * p<0.05; 
1
 number of haplotypes;  
2
 within-population variant sites; 
3
 average 
number of nucleotide differences; 
4
 nucleotide diversity; 
5
 number of haplotypes; 
6
 haplotype diversity. 
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Gene Region Country Year Loci Included N Accession No. Reference 
pvmsp1 SE. Asia Cambodia 2006-2007 42 kDa region 44 JX461286-JX461333 Present Study 
 SE. Asia NW Thailand 2006-2007 Whole gene 65 
GQ890872-GQ890916; 
AF435595-AF435615 
Jongwutiwes 2010 
 SE. Asia S Thailand 2006-2007 Whole gene 67 GQ890975 - GQ891041 Jongwutiwes 2010 
 SE. Asia N Thailand 1997-1998 Whole gene 19 AF435595-AF435614 Putaporntip 2002 
 SE. Asia Bangkok 1997 Whole gene 1 AF435615 Putaporntip 2002 
 
Asia 
Pacific 
Vanuatu 1996,1998 Whole gene 2 AF435632, AF435634 Putaporntip 2002 
 S. Asia India 2004-2007 42 kDa 28 EU430452-EU430479 Thakur 2008 
 S. Asia India 1999 Whole gene 1 AF435639 Putaporntip 2002 
 S. Asia Bangladesh 1994 Whole gene 5 AF435616-AF435620 Putaporntip 2002 
 E. Asia S. Korea 1996-2009 Whole gene 8 HQ171934-HQ171941 Han 2011 
 E. Asia S. Korea 1998 Whole gene 
4 
 
AF435635-AF435638 Putaporntip 2002 
 W. Asia Turkey 2007-2008 Whole gene 30 AB564559-AB564588 Zeyrek 2010 
 S. Amer NW. Brazil 1995,1997 Whole gene 8 AF435622-AF435631 Putaporntip 2002 
pvcsp 
Asia 
Pacific 
Cambodia 2006-2007 Whole gene 47 
JX461243-JX461285, 
KJ173797-KJ173802 
Present Study 
 
Asia 
Pacific 
Thailand 2009* CR 45 HQ011279-HQ011323 N/A 
 S. Asia India 2008* CR 79 FJ491063-FJ491141 N/A 
 E. Asia Korea 2006* CR 20 DQ859736-DQ859767 N/A 
 E. Asia Tibet 2008* CR 37 FJ601724-FJ601761 N/A 
 Oceania 
Papua New 
Guinea 
1999, 2001-
2003 
CR 18 EU031819-EU031836 
Henry-Halldin 
2011 
 S. Asia Sri Lanka 1998-2000 CR 60 JQ362595-JQ362654 Dias 2013 
 S. Amer Columbia 2009 Whole gene 27 GU339059-GU339086 
Hernandez-
Martinez 2011 
 S. Amer Brazil 2004-2005 CR 45 FJ845383-FJ845391 Patil 2010 
 S. Amer Guatemala 2012* CR 7 KC154040-KC154046 
Mendizabal-
Cabrera
†
 
 S. Amer Latin Pacific 2012* CR 24 JQ511263-JQ511286 Gonzalez-Ceron
†
 
 S. Amer Brazil 1997-1999 CR 41 DQ978649-DQ978689 
Santos-Ciminera 
2007 
 S. Amer Honduras 2010-2011 CR 9 JQ903593 - JQ903601 Lopez 2012 
 
Table 2.2 pvmsp1 and pvcsp sequences included in this study. 
The PlasmoDB gene identifier is PVX_099980 for pvmsp1 and PVX_119355 for pvcsp.Indicates the year 
the sequences were made available in GenBank. 
†
Indicates study unpublished but sequences available in 
GenBank. 
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Inter-species McDonald-Kreitman comparisons 
 42 kDa region 42 kDa intervening region 
 Synonymous Non-synonymous Synonymous Non-synonymous 
Fixed 96 93 32 28 
Polymorphic 34 39 10 31 
 p=0.681 p=0.00427 
 
Table 2.3 McDonald-Kreitman test for selection in pvmsp1. 
Evidence for long-term selective pressure on the pvmsp1 42 kDa region and the 42 kDa intervening 
region was assessed with the McDonald-Kreitman test, using P. knowlesi msp1 as the outgroup 
comparator. A Fisher’s exact test (two tailed) was used to determine significance. 
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pvmsp1 Global FST 
0.340 
    
pvmsp1 Pairwise Cambodia India NW Thailand S Thailand 
India 0.031    
NW Thailand 0.000 0.043   
S. Thailand 0.449 0.433 0.366  
Turkey 0.361 0.329 0.403 0.796 
 
Table 2.4 Interpopulation F-statistics for pvmsp1. 
FST values compare the relatedness of a gene among different populations of the same species. Reported 
values compare the relatedness of pvmsp1 42 kDa alleles for pairwise comparisons between Cambodia, 
India, NW Thailand, S Thailand, and Turkey. FST values approaching 0 indicate greater relatedness, while 
values approaching 1 indicate substantial interpopulation variability. Global FST statistic calculated 
between all pvmsp1 populations with n>25 indicates that relatively little genetic distance exists between 
the sampled populations. However, pairwise comparisons demonstrate that some populations exhibit a 
high degree of genetic similarity (Cambodia and India, for example) while other populations are more 
dissimilar (S Thailand and Turkey, for example). 
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pvmsp1 
Global Snn 
0.410* 
Cambodia 
NW 
Thailand 
S  
Thailand 
India      
Cambodia          
NW 
Thailand 
0.318         
S Thailand 0.780 0.865        
India 0.673 0.779* 0.865       
Turkey 0.897 0.946 0.750 0.917      
 
VK210 
Global Snn 
0.517* 
Cambodia Thailand India Korea Tibet PNG 
Sri 
Lanka 
Brazil Honduras 
Cambodia          
Thailand 0.511         
India 0.824 0.778        
Korea 0.950* 0.92 0.977*       
Tibet 0.968* 1.000* 0.686 0.864      
PNG 0.7621 0.633 0.920* 0.923* 0.913     
Sri Lanka 1.000* 1.000* 0.955* 0.958* 0.926* 0.987*    
Brazil 0.844* 0.958* 0.943* 0.955* 0.969* 0.855 1.000*   
Honduras 0.824 1.000 0.976* 1.000 1.000* 1.000* 1.000* 0.881  
Guatemala 1.000* 0.933 0.970* 1.000 0.957* 0.929 0.960* 0.957* 0.708 
 
VK247 
Global Snn  
0.872* 
Cambodia Thailand PNG       
Cambodia          
Thailand 1.000*         
PNG 0.904* 0.939*        
Columbia 1.000* 0.981* 0.935*       
 
Table 2.5 SNN statistics for the pvmsp1 42 kDa region and the pvcsp central repeat region. 
SNN values approaching 1 indicate genetic isolation while values near 0.5 indicate that two geographically 
disparate population may approximate panmixia global and pairwise SNN values show stronger geographic 
clustering among pvcsp VK210 and VK247 repeats than among pvmsp1 42 kDa regions.                                      
* indicates significance to (p<0.05) after Bonferroni correction for multiple comparisons. 
  
31 
 
Figure 2.1 Protein domains and immunologically-relevant regions                                                             
of pvmsp1 42 kDa region and pvcsp. 
For both genes, numbers indicate coordinates according to the Sal1 reference genes. Sequences for 
pvmsp1 (PVX_099980) and pvcsp (PVX_119355) were accessed August 14, 2012 from PlasmoDB.org. 
(A) The pvmsp1 42 kDa region is composed of two primary subunits – a 33 kDa and a 19 kDa subunit. 
Other sub-regions, including the 20 kDa and 14 kDa HARBs have been previously defined and studied. 
Here, we define the region between the HARBs as the “intervening region.” (B) The pvcsp gene is 
composed of three regions – an N-terminal non-repeat region, a central repeat region, and a C-terminal 
non-repeat region. The central repeat region consists of two major nonapeptide repeat types, termed 
VK210 and VK247. Approximate locations of pvcsp regions I and II are noted with horizontal lines in the 
N- and C-terminal non-repeat regions, respectively. 
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Figure 2.2 Geographic distribution of P. vivax populations contributing to this study. 
In total, we identified 13 populations with pvmsp1 42 kDa fragment sequences and 13 populations with 
pvcsp central repeat or whole-gene sequences. These populations were collected from 14 countries, 
pictured above. For countries with n≥10 isolates, the total number of pvmsp1                                                    
and pvcsp isolates is marked. 
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Figure 2.3 Haplotype rarefaction curves for the Cambodian cohort. 
Calculated rarefaction curves are depicted by solid blue (pvmsp1) and red (pvcsp) lines. Dotted lines 
represent rarefaction values extrapolated according to the methods of Cowell, et al. The 95% CIs of 
rarefaction estimates for pvmsp1 and pvcsp are demarked by light blue                                                                 
and light red shaded areas, respectively. 
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Figure 2.4 Nucleotide diversity and Tajima's D across the pvmsp1 42 kDa region                                      
and the whole pvcsp gene. 
Polymorphism (nucleotide diversity, π) (A) and Tajima's D (B) were calculated across the pvmsp1 
amplicon for five diverse populations. A sliding window (50 bp window and 25 bp step size) was used to 
achieve a high resolution analysis. Grey hatches demark the intervening region (nucleotides 4348–4731). 
For pvcsp, N-terminal and C-terminal non-repeat regions were analyzed for nucleotide polymorphism (C) 
and evidence of balancing selection (D) using a sliding window. Putatively panmictic populations are 
marked with a solid line, while populations known to be subject to strong selective forces are marked with 
dotted lines. All coordinates are based on Sal1 pvmsp1 and pvcsp reference sequences. Results of sliding-
window analyses were fairly stable to varying window size (results not shown). 
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Figure 2.5 FST values at polymorphic sites within the pvmsp1 42 kDa intervening region. 
Available parasite populations with n>25 individuals (Cambodia, India, NW Thailand, S Thailand, and 
Turkey) share 42 variable sites within the 42 kDa intervening region of pvmsp1. FST values for each 
variable site were calculated in a pairwise manner between all five populations. FST values approaching 0 
indicate limited inter-population variability at that site, while values approaching 1 indicate substantial 
inter-population variability. Coordinates are reported for every third polymorphic site. 
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Figure 2.6 Neighbor-joining tree of 42 kDa regions from pvmsp1 isolates shows significant 
admixture across geography. 
All unique 42 pvmsp1 population set with n>25 were plotted on a single unrooted, neighbor-joining 
phylogenetic tree. The Sal1 reference sequence is marked in grey. 
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Figure 2.7 Jackknifed consensus trees demonstrate reproducible geographic clustering in pvcsp 
VK210 and VK247 isolates, but not pvmsp1. 
The reproducibility of population clustering was assessed using 1000 jackknifed phylogenies. Individual 
populations clustered together or apart in each of the 1000 jackknifed phylogenies, and the frequency of a 
split between any two populations was quantified. Populations with grey bars (<50% splits) were 
genetically similar, while populations with red bars (>99.9% splits) were highly genetically distinct. 
Phylogenies were built from the pvmsp1 42 kDa region (A), the pvcsp VK210 central repeat (B), and 
pvcsp VK247 central repeat (C). 
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Figure 2.8 Median-joining network of diverse pvmsp1 populations proposes multiple mutational 
paths between geographically diverse populations. 
286 pvmsp1 42 kDa sequences from diverse geographical regions were used as input to create an unrooted 
median-joining network. This network is a visual representation of the mutational paths that may explain 
the observed sequence diversity. Each node represents an allele, node size represents the frequency of that 
allele (range n  = 1 to n = 54), and node color corresponds to country of origin. Cycles within the diagram 
represent alternative evolutionary pathways. Corners represent obligate intermediate sequences that were 
not observed among the sampled alleles. Line length is not proportional to genetic distance. 
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Figure 2.9 Neighbor-joining tree of pvcsp VK210 repeat arrays shows genetic clustering                
according to geography. 
All unique repeat array haplotypes from each pvcsp VK210 population set were plotted on a single 
unrooted, neighbor-joining phylogenetic tree. Visual inspection reveals strong geographic clustering by 
region and country. Latin American sequences are in shades of red, South East Asian sequences are in 
shades of blue, and South and Central Asian sequences are in shades of green. 
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Figure 2.10 Neighbor-joining tree of pvcsp VK247 repeat arrays shows genetic clustering                  
according to geography. 
All repeat array haplotypes from each pvcsp VK247 population set were plotted on a single unrooted, 
neighbor-joining phylogenetic tree. Latin American sequences are in shades of red, South East Asian 
sequences are in shades of blue.
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CHAPTER 3: GENETIC ARCHITECTURE OF ARTEMISININ-RESISTANT MALARIA IN 
CAMBODIA ASSOCIATES WITH PARTNER-DRUG RESISTANCE
2
 
3.1 Introduction 
Mortality due to malaria nearly halved over the last fifteen years, due in part to the adoption of 
artemisinin-based combination therapy (ACT) as first-line therapy. Resistance to ACT represents a major 
threat to malaria control efforts worldwide and has now been reported in five countries in Southeast Asia 
[158]. Efforts are underway to stem the rising tide of resistance in the region, and new antimalarial 
regimens are desperately needed. 
One strategy that has been proposed is the use of triple ACT (TACT) regimens [159]. ACT is 
traditionally comprised of a potent, short-acting artemisinin derivative paired with a longer-acting partner 
drug, such as piperaquine, mefloquine, or lumefantrine. This allows ACT to be administered over just 
three days, but leads to a terminal phase of partner drug monotherapy [160,161]. It has long been 
recognized that, as artemisinin resistance increases and parasites take longer to clear, the probability of 
developing resistance to the partner drug also increases. TACTs would combine two partner drugs with 
artemisinin based on the epidemiologic observation that resistant parasites seem to display sensitivity to 
piperaquine when mefloquine resistant and visa versa [162–164]. 
In western Cambodia, increasing rates of artesunate-mefloquine (AS-MQ) treatment failure led 
Cambodia to adopt dihydroartemisinin-piperaquine (DHA-PPQ) as its first-line ACT in 2012 [163,165]. 
DHA-PPQ failure in Cambodia appears to be due to emerging piperaquine resistance in the setting of 
already established artemisinin resistance [162,163,165,166]. Research into the genetics of artemisinin 
                                                     
2
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co-first and co-senior authors. 
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resistance in Southeast Asia has borne fruit with the discovery of specific resistance markers and their 
association with genetically distinct, clonally expanded parasite populations [166–168]. However, the role 
of ACT partner drugs in shaping these parasite populations has not been explored. 
Using 78 samples collected from three provinces of Cambodia collected between 2011-2014, we 
investigated the genetic architecture of the P. falciparum population using whole genome sequencing. We 
confirmed the genotype of several loci using Sanger sequencing, in particular candidate indels, and 
assessed copy number of resistance loci using real-time PCR and digital droplet PCR. Finding stark 
genetic structuring among the samples, we used population modeling to deduce the origins and recent 
histories of parasite clusters. We then correlated the genetic findings to available ex vivo susceptibility 
data to piperaquine and mefloquine and in vivo response to dihydroartemisinin-piperaquine (DHA-PPQ) 
therapy. We found that piperaquine and mefloquine resistance developed in genetically distinct parasite 
populations that have expanded clonally from a central ancestral population. Our genome-wide data 
confirm that - at present - malaria strains that are highly resistant to piperaquine remain sensitive to 
mefloquine, and vice versa. These findings suggest that ongoing trials to test triple combination therapies 
containing both piperaquine and mefloquine may, in the short term, be effective. However, the emergence 
of triple-therapy resistant P. falciparum remains a distinct threat. 
3.2 Materials and Methods 
3.2.1 Study population 
We studied parasites collected from 78 adults with uncomplicated P. falciparum infection from 
three provinces of Western Cambodia: Oddar Meanchey in the North (n = 61), Battambang (n = 8) in the 
West and Kampot in the South (n = 9). These samples were collected between June 2011 and December 
2013. Sixty of the samples in Oddar Meanchey came from an in vivo efficacy study of DHA-PPQ in 
which 54% of patients developed recrudescent parasitemia requiring  rescue therapy with AS-MQ 
(clinical trial protocol WR1877 [NCT01849640]) [169]. An additional 18 P. falciparum clinical isolates 
from inside and outside of Oddar Meanchey Province were selected at random from an in vitro 
surveillance study (protocol WR1576), for which clinical follow-up data was not collected [170]. Both 
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studies were approved by the Cambodian National Ethics Committee for Health Research and the Walter 
Reed Army Institute of Research Institutional Review Board. The molecular studies described herein 
were approved by the University of North Carolina Institutional Review Board (14-0419). All subjects 
provided informed consent. 
3.2.2 Drug susceptibility testing 
Immediate ex vivo drug susceptibilities to piperaquine and mefloquine were measured using a 
histidine-rich protein 2 (HRP-2) enzyme-linked immunosorbent assay [171–173]. 
3.2.3 Whole-genome sequencing 
Leukodepleted DNA from 91 P. falciparum infections was used for whole-genome sequencing. 
The ratio of parasite DNA to host DNA was determined using a quantitative PCR assay, and isolates with 
≥20% P. falciparum DNA were sequenced on the HiSeq2000 Sequencing System (Illumina, San Diego, 
CA) [174]. Sequence reads were aligned to the P. falciparum 3D7 (v3) genome using the bwa mem 
algorithm. Isolates with 5-fold coverage at ≥60% of the genome were considered for variant calling, 
resulting in calls for 78 isolates. Variant calling was performed using the GATK UnifiedGenotyper utility. 
3.2.4 Candidate markers for piperaquine, mefloquine and artemisinin resistance. 
We confirmed specific candidate gene polymorphisms using alternate methods to assess the 
accuracy of whole-genome calls. We performed PCR and Sanger sequencing to detect microindel IIg in 
the P. falciparum multidrug resistance protein 2 gene (pfmrp2) and to genotype pfmdr1 D1264Y [175–
178]. We conducted evaluation of copy-number variation of candidate loci. This included digital droplet 
PCR to detect X5r domain amplification of chromosome five, previously associated with in vitro 
piperaquine resistance, and reported real time PCR data to assess pfmdr1 copy number amplification, 
associated with mefloquine resistance (with CN≥1.5 considered to represent increased copy number) 
[170,179,180]. We then interrogated the WGS for additional polymorphisms associated with ACT 
resistance, including two other candidate markers of piperaquine resistance (pfcrt C350R and a repeat 
polymorphism in ABC transporter B family member 6), six recently described genetic background 
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markers common to artemisinin-resistant “founders” and the propeller domain of the P. falciparum kelch 
protein K13 (a subset of which had been reported previously) [169,181–183]. 
3.2.5 Assessment of population structure and demography 
Whole-genome variant data were used to determine the principal components of genetic 
variation. Cluster assignments were determined using a nonparametric k-means approach [184], and 
clusters were assigned a unique “Cambodian Parasite” (CP) identifier. Observed minor allele frequencies 
were calculated and compared to the frequencies expected from an idealized population, modeled using 
ms [185]. Pairwise FST for single-nucleotide polymorphisms between sub-populations was calculated and 
rendered in R (R CoreTeam, Vienna, Austria). The folded site-frequency spectrum was used to infer 
demographic parameters and likelihoods under a number of two-population models (split with isolation 
and split with migration) [186]. The clonality of each population cluster was rigorously tested by 
comparing point estimates of linkage disequilibrium decay with bootstrap replicates drawn randomly 
from all sequenced isolates. 
3.2.6 Statistical Analysis 
Median piperaquine and mefloquine IC50 values were compared between PCA clusters using the 
Kruskall-Wallis test. The Wilcoxon-Mann-Whitney test was used to compare the median piperaquine IC50 
values of isolates with and without select candidate resistance markers. Fisher’s exact test was used to 
compare the frequency of increased pfmdr1 CN amongst recrudescent parasites and those that did not 
recrudesce. We analyzed 42-day cumulative risk of recrudescent malaria via survival-analysis with 
Kaplan-Meier curves and compared the risk by cluster using Cox proportional hazards models. Statistical 
analyses were completed using SAS 9.4 (SAS Institute, Cary, NC) and figures generated using R. 
3.3 Results 
We evaluated the IC50 values for piperaquine and mefloquine among our isolates and noted a 
trend of alternate resistance profiles among parasites (Figure 3.1). Evaluation of previously reported 
candidate piperaquine resistance loci showed no correlation with ex vivo resistance (data not shown). 
Mefloquine resistance was correlated to pfmdr1 copy number increases, as previously reported [187]. 
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Whole-genome sequencing produced, on average, greater than ten-fold coverage in 94.7% of 
coding regions and greater than five-fold coverage in 99.5% of coding regions. Variant calling with 
stringent filtering produced 7,228 high-quality SNPs genome-wide within this population. The allele-
frequency spectrum showed overrepresentation of alleles at both minor and intermediate frequencies, 
suggesting underlying population structure and an expanding population (Figure 3.2). Using a principal 
components analysis (PCA) of the genetic variation amongst these samples, we summarized the 
underlying population structure. The first two principal components explained 52% of the variance and 
revealed four distinct population subclusters (Figure 3.3 A-B). Components beyond the third PC were 
less informative (Figure 3.4 A-D). K-means clustering using the top three principal components assigned 
individuals to four genetically distinct clusters (Figure 3.5). We found that dissimilarity was not 
explained by geography, and is therefore driven by a factor that supersedes genetic drift. All clusters 
except for one (named CP4) contained parasites from more than one geographic location (data not 
shown). 
The pattern of opposing drug resistance profiles for piperaquine and mefloquine correlates with 
underlying genetic structure found by whole genome sequencing, a trend that is observed in 
geographically distant sites. Parasite isolates demonstrating higher ex vivo resistance to piperaquine were 
enriched in two clusters - CP3 and CP4 - while mefloquine-resistant parasites were enriched in one cluster 
- CP1. This is depicted in Figure 3.3 A and Figure 3.3 B, where nodes in the PCA represent individual 
clinical isolates and are sized according to their respective piperaquine and mefloquine IC50 values. 
Further comparative analysis of median piperaquine and mefloquine IC50 values by cluster shows 
different drug-resistance profiles among the four groups (Figure 3.3 C-D). The median piperaquine IC50 
values were: 19.3nM (IQR 11.8 to 27.5) for CP1, 36.5nM (17.4 to 45.3) for CP2, 35.5nM (13.4 to 61.3) 
for CP3, and 57.7nM (29.3 to 80.2) for CP4 (Kruskal-Wallis, p=0.002). The median mefloquine IC50 
values were: 143.0nM (IQR 53.9 to 173.9) for CP1, 9.1nM (1.2 to 63.7) for CP2, 47.8nM (23.0 to 62.7) 
for CP3, and 33.1nM (4.8 to 42.7) for CP4 (Kruskal-Wallis, p=0.004). 
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Pairing in vivo data with the PCA results, we found that patients failing DHA-PPQ therapy 
carried parasites that were disproportionately represented in certain clusters and would likely respond to 
AS-MQ salvage treatment. Among the 58 subjects followed for seven weeks after DHA-PPQ treatment, 
there were no recrudescence events in CP1 (n=11, 0%), two in CP2 (n=8, 25%), four in CP3 (n=16, 25%), 
and 18 in CP4 (n=23, 78%). Survival analysis demonstrated that subjects infected with parasites from 
cluster CP4 were more likely to suffer recrudescence after treatment with DHA-PPQ than those from 
other clusters (hazard ratio 7.9, 95% CI 3.0-20, p<0.001, Figure 3.6). All subjects with recurrent malaria 
were treated with AS-MQ per national guidelines [187,188]. After this rescue treatment for the initial 
recurrence, one subject had a second recurrent malaria infection during a limited follow-up period 
(median 15 days, range four to 33 days). Genotyping demonstrated the initial recurrence was not a DHA-
PPQ failure. However, the initial recurrence was the same genotype as the second recurrence after AS-
MQ rescue therapy, suggesting the patient was likely reinfected with a mefloquine-resistant strain. These 
data show no early treatment failures when AS-MQ was given for DHA-PPQ failure, but follow-up times 
were insufficient to rule out late treatment failures. Additionally, data from the original study showed 
only one of 35 (2.9%) recrudescence isolates had increased pfmdr1 CN, whereas ten of 59 (16.9%) initial 
non-recurring isolates had increased CN (p=0.05) [187,188]. 
Parasites in CP2, the central cluster, displayed the least overall partner drug resistance (Figure 
3.3 C-D) and displayed the highest genetic diversity. To explore the hypothesis that CP2 is a potential 
ancestral source population for the other groups, we fit population models based on demographic 
parameters inferred from the allele-frequency spectra within each cluster. Fitting two-population models 
to the CP2-CP1/CP4 cluster pairs demonstrated that CP2 closely resembles an ancestral population that 
gave rise to each of the other subpopulations (Table 3.1). CP3 was unsuitable for model fitting because of 
its extreme clonality. Analysis of linkage decay in each of the four populations revealed a high degree of 
linkage disequilibrium in these populations, indicating that CP1, CP3, and CP4 are clonal or near-clonal, 
suggesting epidemic expansion due to fitness advantages associated with drug resistance to commonly 
used antimalarials (Figure 3.7). The clonal nature and overall low genetic diversity within CP3 and CP4 
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is supported by the distribution of pairwise SNP differences between individuals within the 
subpopulations (Figure 3.8). In order to support the demographic models, we evaluated pairwise FST 
between population clusters. This showed that CP2 is more genetically similar to the outer groups (CP1, 
CP3 and CP4) than the outer groups are amongst themselves (mean FST of 0.41 vs. 0.87, respectively). 
Pairwise FST calculated for the outer groups revealed most polymorphic positions in the genomes to be 
either highly divergent or nearly identical (Figure 3.9). Overall, these findings support the hypothesis that 
CP1, CP3 and CP4 are clonal expansions derived from CP2, an admixed source population. However, the 
extremely low genetic diversity within the CP3 population does not allow us to directly assess the 
alternate hypothesis, that CP4 is not a direct expansion from CP2, but rather a second step in a CP2-CP3-
CP4 demographic history. 
To understand these findings in context of the recent and intensive work in Cambodian P. 
falciparum population genetics, we compared the genetic diversity in our clusters with the genetic 
architecture [38,189]. Miotto et al. identified five distinct compartments of P. falciparum genetic diversity 
in Cambodia [38]. Based on 7,214 SNPs common to both datasets, we determined that our populations 
fall within the scope of diversity described in 2013 (Figure 3.10 A-C), and that CP2 has a genetic 
signature most similar to the admixed KHA population (Figure 3.10 D). 
Analysis of the distribution of candidate piperaquine, mefloquine, and artemisinin resistance loci 
across the four CP clusters highlights the clonal nature of CP1, CP3, and CP4 versus the heterogeneity 
found within CP2, while also showing that the clusters differentiate somewhat by kelch subtype, pfmdr1 
CN profile, and the presence or absence of a full suite of artemisinin-resistance background markers 
(Figure 3.11). CP2, the diverse source population, generally contains parasites with fewer artemisinin-
resistance background markers; 15 of 21 (83%) possess at least one wild type allele, and five (28%) 
possess multiple wild type alleles. As expected, four of the five parasites with multiple wild type alleles 
remain wild type at the kelch13 locus. In contrast, CP1, CP3, and CP4 parasites carry nearly the full set of 
artemisinin resistance background markers accompanied by kelch mutations. CP3 and CP4, the 
piperaquine-resistant clusters, contained parasites that generally harbored the kelch13 C580Y mutation 
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and, by and large, did not display increased copy number at pfmdr1 or contain the pfmrp2 microindel. 
Conversely, the mefloquine-resistant CP1 parasites were primarily kelch13 R539T mutants, many 
displayed increased pfmdr1 CN, and all tested isolates carried the pfmrp2 microindel II-g. None of the 
samples differed in their genotypes at several candidate piperaquine resistance loci (pfcrt C350R, X5r 
copy number, and mdr6 repeat). 
3.4 Discussion 
3.4.1 Associations between population structure and partner-drug IC50 in Cambodia 
Our findings show that resistance to piperaquine and mefloquine has developed on distinct 
genetic backgrounds that are not explained by geography. These findings have important clinical and 
public health implications. They help explain the phenomenon that AS-MQ rescue therapy is successful 
in individuals who fail DHA-PPQ treatment, and they suggest that, in the short term, AS-MQ will remain 
effective in the setting of DHA-PPQ failure. 
Currently, trials of triple artemisinin combination therapies (TACTs) are underway in Cambodia 
[190]. These are predicated upon evidence that the mechanisms of MQ and PPQ resistance may be 
antagonistic. Mefloquine resistance has been shown to sensitize parasites to piperaquine in vitro, which 
mirrors historical observations of a reciprocal relationship between chloroquine (a relation of piperaquine) 
and mefloquine resistance [191–193]. Similarly, artesunate-amodiaquine (ASAQ) and artemether-
lumefantrine (AL), regimens commonly used in Africa, have been found to exert opposing selective 
effects on parasite polymorphisms in the pfmdr1 and pfcrt genes [194,195]. Our findings are largely 
consistent with these prior observations. Specifically, the most mefloquine-resistant subgroup (CP1) was 
the most piperaquine sensitive, the most piperaquine-resistant subgroup (CP4) was the most mefloquine 
sensitive, and no parasites were strongly resistant to both mefloquine and piperaquine. Moreover, recent 
studies in western Cambodia have shown declining pfmdr1 copy number amplification as piperaquine 
resistance emerged [196–198]. Our study suggests that the loss of pfmdr1 duplications is not the result of 
copy-number deamplification, acquisition of piperaquine resistance, and then expansion of the same 
parasite clones, but rather expansion of very different genetic clones associated with piperaquine 
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resistance. These lines of evidence suggest that resistant parasites in Cambodia tend to represent 
multidrug resistant lines (based on ex vivo resistance data to other antimalarials not reported here), 
resistant to either piperaquine of mefloquine, rather than extensively drug resistant lines resistant to both 
partner drugs. This would mean that TACT would target non-overlapping drug-resistant populations, 
likely increasing the overall efficacy of initial therapy for malaria. 
Despite this evidence in support of TACT trials, our data present some unsettling findings. First, 
several isolates remain sensitive to both drugs, raising the concern that resistance to both partner drugs 
may emerge within these isolates by a novel mechanism if TACTs are implemented. Secondly, rare 
parasites among CP3 and CP4 groups had increased pfmdr1 copy number - a genetic marker of MQ 
resistance. These findings could be of no import to public health, or they could be a harbinger of triple-
therapy resistant P. falciparum. 
Whole-genome sequencing allowed us to appreciate clinically relevant substructure and 
population histories. Our findings suggest that the partner-drug resistant subpopulations (CP1, 3, and 4) 
have undergone, or are currently undergoing an epidemic expansion. These subgroups harbored nearly the 
full set of artemisinin-resistance background markers, were uniformly kelch13 mutants, and demonstrated 
increased IC50 to either mefloquine or piperaquine. While the CP3 and CP4 populations overlap 
previously described subpopulations in Cambodia (Figure 3.10), a higher percentage of our isolates 
appear in these CP3 and CP4 populations compared to the previous studies, suggesting a recent 
expansion. Within-subpopulation pairwise genetic diversity (defined as the number of SNPs between the 
isolates) is much lower for CP1, 3, and 4 as compared to the CP2 subpopulation (Figure 3.8), causing 
elevated linkage disequilibrium within these subpopulations (Figure 3.7). Demographic modeling brings 
further clarity to the history of these subpopulations. Our models suggest that CP2 acted as a source from 
which CP1 and CP4 split and underwent clonal expansion (the low diversity in CP3 precluded these 
models). Consistent with epidemiological data that MQ-resistance arose in Cambodia prior to PPQ-
resistance [199,200], we found that the MQ-resistant CP1 subpopulation separated from CP2 prior to the 
separation of the PPQ-resistant CP4 subpopulation (Table 3.1). 
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A concerning finding was that the expanding CP4 subpopulation had a strikingly high 
recrudescence rate after DHA-PPQ therapy. It is unknown what genetic drivers may cause this phenotypic 
difference between CP4 and CP3, which also had overall elevated DHA-PPQ IC50 values. FST 
comparisons between these two populations showed large genomic regions of near perfect homology 
contrasting with regions of high divergence. These findings support - but cannot pinpoint - yet-
undiscovered genetic variation that confers increased parasite fitness to CP4 parasites. Additional studies 
involving larger numbers of well characterized samples with elevated piperaquine IC50 will help elucidate 
the mechanistic differences between CP3 and CP4 parasites, and have the potential to uncover elusive 
genetic markers of piperaquine resistance and clinical failure. As our samples were collected during the 
early emergence of piperaquine resistance in Cambodia with modest increases in IC50, ongoing sample 
collection and genomic surveillance will be crucial for understanding how these subpopulations continue 
to evolve. 
It is clear that artemisinin resistance has had profound effect on the population structure in 
Cambodia [201,202] (for example, the high prevalence of R539T in CP1 and of C580Y in CP3 and 4). 
Unfortunately, ex vivo artemisinin phenotype data by the ring-stage survival assay [203] are unavailable 
for these samples, precluding ex vivo evidence regarding the extent of artemisinin resistance in these 
subpopulations. Overall, only five of the 78 samples that underwent whole-genome sequencing in our 
study did not harbor kelch13 mutations, but these five samples still harbored multiple mutant artemisinin 
resistance background markers believed to be conducive to the acquisition of a kelch13 mutation (Figure 
3.11) [201]. This is consistent with previous population genetic studies showing that P. falciparum 
parasites in the region have undergone an extreme, recent genetic bottleneck due to artemisinin selection 
pressure that has resulted in groups of highly differentiated clonal subpopulations [201,204] . The fact 
that these background markers are largely fixed in our cohort does not bode well for the therapeutic 
lifespan of future partner drugs used in ACT in the region. As many have remarked, ACT in its current 
form (two drugs for three days) may no longer be a viable strategy in Southeast Asia [199,205]. 
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In conclusion, we used a population genetics approach to provide insight into the differing 
genetic backgrounds upon which piperaquine and mefloquine resistance occur in Cambodia. Although 
our study was limited to a single country, the findings and methods are likely applicable to other countries 
in Asia where ACT resistance is actively spreading [204]. As reports of ACT failure become more 
commonplace, further study of partner-drug resistance throughout the region and evaluation of novel 
ACT regimens is imperative. 
3.4.2 Data Availability 
Sequencing reads were deposited at the Sequence Read Archive [SRP063498]. Sequences for pfmdr1 
[accessions KT833623-740] and pfmrp2 [KT876268-381] amplicons were deposited at GenBank. 
3.4.3 Author Contributions  
CMP, JBP, JTL, CL, DLS and JJJ designed the study. CMP, JBP, SB, JTL, JJJ, CAL, CL, DLS, SC, and 
PG collected the data. CMP, JBP, SB, SC, PG, EB, CAL, CL, DLS, JTL, and JJJ did experiments and 
analyzed the data. CMP, JBP, JTL, DLS and JJJ interpreted the data and prepared the report. JTL, JJJ, CL 
and DLS oversaw the project. 
3.4.4 Funding 
This work was supported by the National Institutes of Health and the National Instutute of Allergy and 
Infectious Diseases [5T32AI007151 to JBP, T32GM007092 and F30AI109979 to CMP, R01AI089819 to 
JJJ, and K08 AI110651 to JTL]; the Armed Forces Health Surveillance Center/ Global Emerging 
Infections Surveillance and Response System; Military Infectious Disease Research Program; and the 
American Society of Tropical Medicine and Hygiene/Burroughs Wellcome Fund [fellowships to JTL and 
CMP]. The funders had no role in study design, data collection and analysis, decision to publish, or 
preparation of the manuscript.
52 
 
Data Model θ s ηCP2 ηX mCP2→X mX→CP2 TSPLIT Log Likelihood AIC
†
 
CP2-CP1 Static 382.98 - - - - - - -3202.43 6406.86 
CP2-CP1 Iso 388.13 0.866 18.13 0.05 - - 0.074 -340.90 691.80 
CP2-CP1 IM 367.55 0.999 5.45 0.051 0.165 0.129 8.531 -251.80 517.60 
CP2-CP3 Static * * * * * * * * * 
CP2-CP3 Iso * * * * * * * * * 
CP2-CP3 IM * * * * * * * * * 
CP2-CP4 Static 363.92 - - - - - - -3717.13 7436.26 
CP2-CP4 Iso 365.19 0.947 18.11 0.053 - - 0.092 -231.71 473.42 
CP2-CP4 IM 374.68 0.185 4.47 0.052 0.339 2.61 0.023 -218.08 450.16 
 
Table 3.1 Inferred parameters for demographic models. 
Best-fit inferred parameter estimates for alternative two-population models fit between CP2 and 
CP1/CP3/CP4. Static models no split and no growth (positive or negative). Iso models a split with 
subsequent fluctuating population sizes but without migration. IM models a split with subsequent 
fluctuating population sizes and migration. The parameter s is the proportion of an ancestral combined 
population that gave rise to CP2, while 1 - s is the proportion of the ancestral population that gave rise to 
either CP1/CP3/CP4. η1 and η2 are the effective population size of CP2 and CP1/CP3/CP4, respectively. 
m1→2 is the migration rate from CP2 to CP1/CP3/CP4. m2→1 is the migration rate from CP1/CP3/CP4 to 
CP2. TSPLIT is the time since the two populations split, measured in θ generations. θ is the population 
mutation rate. 
†
 AIC: Akaike Information Criterion; * Population CP3 was not amenable to model fitting 
because of its high clonality. 
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Figure 3.1 Piperaquine and mefloquine IC50 values associate                                                             
with parasite subpopulations in Cambodia. 
Subjects who had both piperaquine and mefloquine IC50 values are displayed. Those who later had an 
episode of recrudescence are displayed using solid orange triangles, while those who did not have an 
episode of recrudescence or did not have follow-up data available are displayed using solid navy circles. 
Two isolates that had recrudescence with very high piperaquine IC50 values (307.0 and 397.1nM)           
are represented with hollow symbols. 
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Figure 3.2 Allele frequency spectrum demonstrates an excess of low-frequency                                        
and intermediate-frequency alleles. 
A folded allele frequency spectrum for synonymous (red), nonsynonymous (orange), genic (light blue) 
and intragenic variants (dark blue) regions are shown for the 78 Plasmodium falciparum isolates. The 
population has an excess of low frequency alleles, similar to other P. falciparum populations, and 
suggestive of a population expansion. However, an excess of intermediate frequency alleles is also 
observed when compared to expected values under a neutral evolution model, suggesting substructuring. 
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Figure 3.3 Principal components analysis demonstrates distinct clusters                                                   
with non-overlapping resistance profiles. 
In the upper panels, nodes are scaled according to IC50 values, with the largest nodes representing IC50 
values of 200nM or greater. Panel (A) displays piperaquine IC50 values, and panel (B) displays 
mefloquine IC50 values. Blue samples represent with cluster CP1, red with CP2, green with CP3 and 
yellow with CP4. In the lower panels, IC50 values by cluster are depicted for piperaquine in panel (C) and 
mefloquine in panel (D). Boxplots display the median (horizontal line), interquartile range (box), and the 
lowest and highest data point within 1.5 times the IQR (whiskers) of IC50 values [values outside this range 
are plotted as individual points]. Two outliers with piperaquine IC50 values of 307.0 and 397.1nM were 
clipped from cluster CP4 in panel (C) and labeled with an asterisk (*). There was a statistically significant 
difference among the four groups for piperaquine (p=0.002) and for mefloquine (p=0.004) IC50 values. 
Noise was added to reduce overplotting. Abbreviations: PC, principal component;                                            
IC50, half-maximal inhibitory concentrations. 
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Figure 3.4 Eigenanalysis demonstrates that the majority of genetic diversity is described                         
by the top three principal components. 
Eigenvalues are presented in (A), demonstrating that the top three components describe over 60% of 
genetic diversity in this population. (B, C, D) show genetic differentiation among sequenced isolates, as 
described by the top principal components. In each view, clear separation is seen between subpopulations. 
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Figure 3.5 K-means clustering identifies four genetic clusters. 
Increasing the number of clusters from n=3 to n=4 yields a substantial improvement in Bayesian 
information criterion (BIC). While subsequent increases do yield BIC improvements, the improvement in 
goodness of fit is not commensurate with the cost associated with increased degrees of freedom.  
58 
 
Figure 3.6 Recrudescence after DHA-PPQ therapy is associated with the CP4 cluster. 
Kaplan-Meier curves demonstrate the risk of recrudescence by cluster (Wald p<0.001 for CP4 compared 
to other clusters). Red crosses represent patients censored for withdrawal                                                             
or development of new infection. 
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Figure 3.7 Parasites in drug-resistant subpopulations have extended linkage disequilibrium (LD), 
supporting clonal expansion. 
The extent of clonal expansion among the P. falciparum clusters was determined by assessing linkage 
decay (r
2
). Point estimates of linkage decay for each of the clusters were calculated pairwise between 
variants up to 200,000 bases apart, and are shown by colored lines. CP3 is absent because its extreme 
clonality prevented calculation of r
2
. To determine the significance of these results, a null distribution of 
linkage decay was calculated from 100 bootstrapped subpopulations,                                                   
drawn randomly with replacement from the 78 P. falciparum samples. 
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Figure 3.8 Parasites in drug-resistant subpopulations have decreased pairwise SNP differences, 
consistent with clonal expansion. 
For each CP group, the number of pairwise SNP differences was calculated and plotted. CP3 and CP4 
have substantially lower numbers of pairwise SNP differences between isolates, consistent with the 
hypothesis that these are clonally expanding subpopulations. 
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Figure 3.9 Pairwise FST comparison of four P. falciparum subpopulations pinpoints identical and 
divergent genomic regions between subpopulations. 
Each circular track represents the pairwise FST comparison for all genes (dots) between the reported CP 
populations. Each segment of the track represents a chromosome, which are numbered in the center of the 
figure. Within each track, the lower and upper y-axis limits are zero and one, respectively. FST values at 
or approaching zero indicate that a locus is genetically similar between the two populations, and FST 
values at or approaching one indicate that a locus is genetically dissimilar between the two populations. In 
particular, the comparison between CP3 and CP4 (the inner-most track) highlights identical and divergent 
genomic regions, providing clues for the genetic determinants of piperaquine resistance                                   
and clinical outcomes.  
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Figure 3.10 Comparisons of P. falciparum clusters with previously described                               
Cambodian subpopulations. 
Panel (A-C) displays projections for the top three principal components for analysis of 78 P. falciparum 
isolates sequenced in this study (CP1 as blue, CP2 as red, CP3 as green, CP4 as yellow), compared to 293 
isolates previously described Cambodian isolates (gray) from Pailin, Pursat, Ratanakiri, and Tasanh 
(Miotto et al., 2013). The scope of genetic diversity described in the present study falls within the range 
previously described. Panel (D) displays comparisons of allele-frequencies between CP2 (the founder 
population described in the present study) with previously described Cambodian subpopulations (KH#). 
Of the 1886 subpopulation-defining variants described by Miotto et al. in 2013, 619 of these were also 
used in this study as markers of genetic diversity, and the allele frequency at these markers were used for 
matching. Comparisons were bootstrapped 1000 times, and the boxplots display the median (horizontal 
line), IQR (box), and 1.5 times the IQR (whiskers). CP2 is most genetically similar to the KHA subgroup. 
Noise has been added to the PCA to reduce overplotting. 
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Figure 3.11 Haplotype map describing associations between piperaquine and mefloquine IC50 
values and genotypes of known and candidate markers of resistance. 
IC50 values are displayed in gray scale, with lighter shades indicating lower IC50 values and black 
indicating samples with values ≥200nM. Additional columns code data, with blue blocks indicating wild-
type (3D7) genotype, red blocks indicating the presence of the mutation of interest, and yellow blocks 
indicating missing data. We also included both known and candidate markers for artemisinin (including 
recently described candidate background resistance markers), mefloquine, and piperaquine. 
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CHAPTER 4: DIFFERING MECHANISMS OF POPULATION-LEVEL RESILIENCE FOR 
CO-ENDEMIC PLASMODIUM VIVAX AND PLASMODIUM FALCIPARUM
3
 
4.1 Introduction 
Western Cambodia, which is the site of emerging artemisinin-resistant Plasmodium falciparum 
[206,207], has been the focus of intense multimodal malaria-control interventions. These interventions, 
which were designed to contain artemisinin resistance in P. falciparum, have included increased vector 
control, increased surveillance, and improved access to quality artemisinin-combination therapy (ACT) 
[208]. Although these interventions were intended to curtail P. falciparum malaria, enhanced diagnosis 
and treatment and use of insecticide treated bednets are also effective against P. vivax malaria. P. vivax 
and P. falciparum affect the same populations and are transmitted by the same mosquito species in this 
region [209]. As a result of containment efforts, between 2009 to 2013 there was an 81% decrease in total 
malaria infections. While there has been a marked decline in P. falciparum cases, P. vivax cases have 
increased and are now more common than P. falciparum [210]. P. vivax has proven its resilience 
throughout the Mekong region as it has become the predominant species [211–213]. Despite the failure of 
these interventions to contain artemisinin resistant P. falciparum, they have created a natural experiment 
in which the genomic responses of sympatric P. falciparum and P. vivax populations can be studied. This 
contrast in outcomes for the Cambodian P. vivax and P. falciparum populations raises a question - what 
are the genetic signals that correlate with population-level resilience for these two species, and how do 
they differ. 
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Because both P. falciparum and co-endemic P. vivax are affected by many control interventions, 
studies inclusive of P. vivax are needed. Sympatric populations provide a vehicle for understanding 
differences in transmission dynamics, population structure, and life history. Importantly, they provide a 
means for understanding how these species respond differently to control interventions. They may also 
provide a proving ground for policies that address the elimination of both P. vivax and P. falciparum. The 
few published population genetics studies of sympatric P. vivax and P. falciparum populations have 
revealed key insights into the differences between these two species. Microsatellite studies conducted in 
the Solomon Islands, Papua New Guinea, Indonesia, and Cambodia have painted a consistent picture of 
higher genetic diversity in P. vivax populations than in sympatric P. falciparum populations [214–217]. 
Additionally, these reports detail that P. falciparum populations tend to be clonal with episodic 
transmission and structure-by-geography, while P. vivax populations enjoy a higher effective population 
size, more stable transmission, and increased gene flow between geographic islands. Studies of ama1 in 
sympatric populations uncovered similar trends [218,219]. 
These studies of sympatric parasite populations spawn as many questions as they resolve. 
Specifically, it is unclear why this pattern of higher P. vivax diversity and more consistent transmission 
are repeated across continents and time. On a basic level, we need to know whether these results are 
driven by species-specific differences in microsatellite and antigen mutation rates, and if they hold up at a 
whole-genome level. If these differences are real, are they a result of control programs doing a poorer job 
at attenuating P. vivax transmission (for example because transmission can occur at lower parasitemias 
and even before clinical disease is recognized, or because there is a reservoir of genetic diversity in the 
dormant hypnozoites among the population), or do P. vivax parasites simply respond differently to similar 
assaults. If mechanistic differences do account for these differences, what additional information is 
needed before these insights can be translated into intervention? The answers to these questions may aid 
in designing elimination programs that address both P. vivax and P. falciparum effectively. 
Genome-by-population studies of sympatric P. vivax and P. falciparum isolates can help answer 
these questions. Importantly, whole-genome studies can peer into demographic history and also 
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comprehensively search for loci subject to selective pressures. The population genetics of the P. 
falciparum parasites in artemisinin-resistance-era Cambodia have been carefully studied [220–222]; 
however, an in-depth genomic study of P. vivax in Cambodia during the resistance-containment campaign 
is lacking. 
To understand the genome-wide species-specific patterns of selection in sympatric P. vivax and 
P. falciparum populations in Cambodia, we conducted whole-genome sequencing of co-endemic parasites 
sampled from a primary site and two nearby sites. These sites were designated as “Zone 2” during the 
containment campaign, and as such were subject to comprehensive and multimodal malaria control efforts 
[223]. Using these data, we compared P. vivax and P. falciparum population structure, polyclonality, and 
selection signatures to uncover differences in how these two species respond to malaria control and 
elimination efforts. 
4.2 Materials and Methods 
4.2.1 Sample Collection 
Clinical isolates were collected from 2009-2013 by the Armed Forces Research Institute of 
Medical Sciences in three Cambodian provinces - Oddar Meanchey (northwest), Battambang (west), or 
Kampot (southwest). Uncomplicated P. vivax or P. falciparum malaria patients presenting to study-site 
clinics gave written informed consent for their participation in this study. Study staff collected and 
leukodepleted venous blood, and administered treatment in accordance with Cambodian National Malaria 
Control Program guidelines. During this period, both P. falciparum malaria monoinfections and mixed P. 
falciparum and P. vivax malaria infections were treated with dihydroartemisnin-piperaquine (DHA-PPQ). 
While chloroquine (CQ) was the primary antimalarial used for P. vivax monoinfection during this period, 
the concerns for chloroquine resistance in Cambodia led to a change to DHA-PPQ as the treatment of 
choice for vivax malaria in 2012. Molecular studies were approved by the IRB at the University of North 
Carolina, some other IRB, and the Cambodian National Ethical Committee for Health Research. 
P. vivax and P. falciparum sample sequencing. For P. vivax, to remove contaminating host DNA, 
whole blood was leukodepleted using Plasmodipur™ filters (Euro-Diagnostica®, Malmö, Sweden). The 
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ratio of parasite-DNA to host-DNA was determined using a qPCR assay [224], and isolates with ≥20% P. 
vivax DNA were considered for sequencing. Clinical isolates with high plasmodium:human DNA content 
were sequenced on the HiSeq2000™ or HiSeq2500™ using 100 or 125 base-pair paired-end chemistry 
(Illumina, San Diego, CA). Data are made available at the Sequence Read Archive, and accessions are 
listed in Table 4.6. For P. falciparum, data from previously reported isolated were used and reanalyzed in 
this study to allow for comparable analysis methods between species. More stringent analysis filters 
altered the number of variants called compared to previous reports (Parobek et al., in submission). 
4.2.2 Sequence Analysis 
Sequence reads were aligned to the P. falciparum 3D7 (v3) and P. vivax Sal1 (v3) genomes using 
bwa mem [225], which allows for a hybrid end-to-end and local alignment approach. To increase 
sensitivity through hypervariable regions, we increased the clip penalty for local alignment to L=15, 
which was the minimum value that allowed for with default sensitivity. PCR and optical duplicates were 
removed from alignments using the Picard Tools MarkDuplicates utility [226] and local realignment of 
highly entropic regions was performed using the GATK  IndelRealigner utility. Isolates with five-fold 
coverage at ≥80% of the genome in the case of P. vivax, and ≥60% of the genome in the case of P. 
falciparum, were considered for variant calling and further analyses. 
Variant calling for P. falciparum was performed as described previously (Parobek et al., in 
submission). Variants were called for P. vivax samples jointly using the GATK UnifiedGenotyper 
[227,228]. Variants were filtered stringently using cutoffs responsive to the underlying distribution of 
quality scores: Quality-by-Depth (QD) ≥ 25, Mapping Quality (MQ) ≥ 55, Fisher Score (FS) ≤ 10, Map-
Quality Rank Sum ≥ -5.0, and Read Position Rank Sum ≥ -5.0, extreme Filtered Depth ( DP ≤ 10th and ≥ 
90
th
 percentile), and an overall quality (QUAL) below the log-scaled inflection point. In addition, only 
biallelic variant records with at least 5-fold coverage in 100% of isolates were considered. Variants in 
low-complexity regions were identified using Tandem Repeat Finder [229] and excluded. Members of 
highly paralogous gene families [230] were excluded. Furthermore, we excluded 60000 bases of sequence 
space from the beginning and end of each chromosome. 
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4.2.3 Tests for Within-Host Diversity 
To test whether infections were multiclonal or polyclonal, we used the FWS statistic [231,232]. To enable 
direct FWS comparisons between P. falciparum and P. vivax isolates, which had different numbers of loci, 
we bootstrapped each calculation 1000 times, selecting 5000 variable sites for each isolate and each 
replicate. The maximum and minimum FWS bootstrap values were identified to provide a generous upper 
and lower confidence interval for each FWS whole-data point estimate. Additionally, P. vivax isolates were 
screened for multiplicity of infection (MOI) using ultra-deep sequencing of the highly polymorphic 
pvmsp1 locus [233], which is more sensitive to complex infections than microsatellite fragment analysis 
[234]. Deep-sequencing of the pvmsp1 locus was performed using the Ion Torrent platform, and the reads 
for each individual were clustered using SeekDeep, an iterative de novo clustering algorithm (Hathaway, 
in submission; github.com/bailey-lab/SeekDeep). Experimental procedures were performed as previously 
described [234]. For the purposes of the present study, a sample was deemed multiclonal if a minor clone 
existed at ≥ 10% read frequency. 
4.2.4 Tests for Population Structure 
We determined population substructuring using principal component analysis (PCA) and cluster 
assignments were determined using a nonparametric k-means approach. PCA was calculated using 
adegenet [184]. 
4.2.5 Demographic Inference 
Five one-population demographic scenarios were fit to the observed site-frequency spectra at 
synonymous sites in both the P. vivax and P. falciparum populations [235]. First, a model of constant 
population size was fit in which there is no increase or decline in the effective population size over time. 
Second, a model of population decline was fit, in which the effective population size began to decrease at 
some time, T, in the past. Third and fourth, exponential and two-epoch growth models were fit, in which 
the effective population size began either exponential growth or a sudden size change at T. Finally, a 
“bottleneck” scenario of sudden decline followed by exponential growth was fit. For each model, the 
following parameter space was explored as applicable: time (T, 0.01 - 5.0), the factor of population 
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contraction (ηD, 0.001 - 1.0) and expansion (ηG, 1 - 100), and the ancestral θ. One hundred independent 
runs were performed for each model and each dataset. Inter-run parameter values were compared to 
assess model convergence, and the run with the highest log-likelihood was selected.  
4.2.6 Detecting Patterns of Selection 
Inferred parameters for the best-fit one-population demographic scenario for both P. falciparum 
and P. vivax were used to parameterize coalescent simulations. Each gene in the genome (excepting genes 
from highly paralogous families and in chromosomal telomeres) was simulated 1000 times using the R 
package coala [236], a wrapper for ms [237]. The resulting dataset represented a model population with 
the same demographic history as our Cambodian P. vivax and P. falciparum populations, but provided a 
null distribution for population genetic tests. From this resource, we determined a null distribution for 
Tajima’s D values for both P. vivax and P. falciparum to aid in identifying genes under unexpectedly 
strong balancing or directional selection. 
4.2.7 Copy-Number Analysis 
Due to the high AT content of the P. vivax and P. falciparum genomes, we identified copy-
number variants using a tailored approach for identifying segmental duplications in genomes with high 
AT content (DeConti, in submission). Predicted copy-number variants were confirmed using a 
probabilistic framework for structural variant discovery [238], and a subset of P. falciparum mdr1 copy 
number variants were confirmed using qPCR as described previously (Parobek et al., in submission). 
4.2.8 Scans for Positive Selection 
Because there is as yet no fine-scale map of recombination for the P. vivax genome, we initially 
sought a map-independent haplotype-based approach. nSL, a modification of iHS, obviates the need for a 
genetic map, reduces its dependence on recombination and demographic events [239], and may afford 
increased sensitivity to detect soft selective sweeps. This statistic has proved sensitive in identifying 
selection in other non-model organisms [240]. As a secondary test, we constructed a genetic 
recombination map for both P. falciparum and P. vivax using LDhat interval [241] and performed the iHS 
haplotype-based test for directional selection [242]. iHS was calculated using iHH0/iHH1, where 
70 
subscripts 0 and 1 arbitrarily denote alleles, agnostic to ancestral or derived status. For both nSL and iHS, 
because of the lack of outgroup sequences, we ignored the sign. We plotted iHS and nSL scores that were 
normalized according to allele frequency bins. Extended haplotype homozygosity (EHH) was calculated 
for the selected and unselected allele. These three haplotype-based tests for selection were performed 
using the program selscan [243]. 
4.3 Results 
4.3.1 Sequencing sympatric P. vivax and P. falciparum populations 
We generated whole-genome short sequence reads for 78 Cambodian P. vivax field isolates and 
93 P. falciparum field isolates, and aligned these sequence data to the Sal1 and 3D7 reference genomes, 
respectively. Among P. vivax isolates, 70 (90%) had five-fold or greater coverage across at least 80% of 
the genome, while among P. falciparum isolates, 80 (86%) had five-fold or greater coverage across at 
least 60% of the genome. Beyond tandem repeats, we excluded from analysis roughly 4 Mb of sequence 
space from both the P. vivax and P. falciparum genomes, containing approximately 300 and 400 genes, 
respectively. These were primarily subtelomeric regions containing members of highly paralogous gene-
families. In total we identified 61,448 high-quality P. vivax SNPs and 6,734 P. falciparum SNPs. 
4.3.2 P. vivax infections are more complex than P. falciparum 
Because Plasmodia infections are frequently multiclonal, we investigated the extent of 
multiclonality among our sequenced field isolates. P. vivax infections were more polyclonal (defined as 
FWS < 0.95) than P. falciparum infections (p<0.0001, Fisher’s exact), a finding which remained 
unchanged after bootstrapping to account for the difference in the number of variants identified (Figure 
4.1). To confirm the extreme polyclonality predicted for P. vivax by FWS, we deep sequenced the 
hypervariable region of the 42kda domain of the merozoite surface protein 1 (pvmsp1) (identified in [244] 
and used in [245]). Amplicon deep sequencing confirmed the highly multiclonal nature of P. vivax 
infections: of the 52 P. vivax isolates from Oddar Meanchey province, 47 isolates were able to be deep 
sequenced, of which 24 (51%) were multiclonal. Furthermore, these results were in good agreement with 
FWS results: 17/21 isolates with an FWS ≥ 0.95 were monoclonal by pvmsp1 sequencing, while 19/26 
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isolates with an FWS < 0.95 were multiclonal (Fisher’s exact test p=0.0004). Subsequent to this, most 
analyses were performed both for the 28 P. vivax infections that were monoclonal by the FWS metric and 
for all P. vivax samples (i.e. multiclonal and monoclonal infections) to assess the effect of multiclonality 
of our results. 
4.3.3 Determining within-population genetic diversities 
Principal component analysis (PCA) revealed no population substructure among P. vivax isolates. 
In contrast, we previously showed that P. falciparum parasites were partitioned into subpopulations, and 
we confirmed these findings with a more stringent variant calling analysis here (Figure 4.2) (Parobek et 
al., in submission). These partitions do not correspond to collection site, date of collection, or multiplicity 
of infection. To confirm visual inspection of partitioning, we used k-means clustering to identify the 
number of P. vivax and P. falciparum clusters present. K-means clustering confirmed that all P. vivax 
isolates were part of a single cluster, and that the P. falciparum was subdivided into four clusters (Figure 
4.3). As described previously (Parobek et al., in submission), the central P. falciparum population (here 
referred to as CP2) is most closely related to the admixed P. falciparum described by Miotto et al. [246] 
and likely represents the founder population for the other populations. Henceforth most analyses were 
performed both using all P. falciparum samples and using the 18 parasites of the central admixed 
population (known as CP2). 
4.3.4 Type and timescale of demographic events 
To better understand the differences in the population structures, we first examined the allele 
frequency spectra (AFS) of P. vivax and P. falciparum populations. Spectra were calculated by variant 
type (synonymous, non-synonymous, genic, and intergenic) and compared to the spectrum expected in a 
simulated coalescent population with no natural selection, constant population size, and complete random 
mating (Figure 4.4). We also determined the AFS among P. vivax monoclonal infections and among the 
parasites in the P. falciparum complete population and CP2 population alone. We observed an excess of 
intermediate-frequency derived alleles in the collective Cambodian P. falciparum AFS, with a local 
maximum at 19 - 21. This intermediate peak is likely driven by the presence of multiple parasite P. 
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falciparum subpopulations, and when the core CP2 subpopulation alone was analyzed, these excess 
intermediate frequency alleles disappeared (Figure 4.5). In contrast to the P. falciparum case, we 
observed an excess of low-frequency derived alleles in the Cambodian P. vivax AFS (both entire 
population and monoclonals only) compared to the neutral simulations, which suggests a population 
expansion. We used these qualitative comparisons as priors to inform demographic model selection. 
To choose a best-fit demographic scenario and identify optimal population parameters, we 
adopted an efficient diffusion approach, which approximates a population of N individuals varying 
through discrete generations. Using this approach, the following demographic scenarios were fit to 
observed P. vivax and P. falciparum allele frequency spectra - constant population size, decline, 
exponential increase, two-epoch increase, and bottleneck with subsequent exponential growth. Toy 
scenarios are provided in Figure 4.6. We used the Akaike Information Criterion (AIC) to inform model 
selection. For both P. vivax (all samples and monoclonals only) and the P. falciparum CP2 (core 
population only) datasets, the positive exponential growth model was the best-fit model (Table 4.1-1.3). 
Interestingly, when considered as a whole, the best-fit model for the entire P. falciparum population, 
which includes satellite populations that are likely clonal expansions of multidrug-resistant parasites 
(Parobek et al., in submission), was one of bottleneck and extreme growth. The best-fit models predicted 
that the P. vivax population has been expanding resulting in a larger effective population size (θ=850 for 
P. vivax monoclonals with best fit exponential growth model) than the sympatric P. falciparum 
population (θ=240 for P. falciparum CP2 with best fit exponential growth model). 
4.3.5 Selection and sweeps on orthologous genes 
The population structure of P. falciparum in Cambodia has been shaped by the intensive use of 
artemisinins and their partner drugs [246,247] (Parobek et al., in submission). Previously, we showed that 
this structure likely includes and admixed founder population (CP2) with clonal expansion of three other 
populations (Parobek et al., in submission). However, little is known about the selective forces that shape 
the P. vivax population. To understand the selective landscape shaping the P. vivax and the admixed P. 
falciparum population (CP2), we used LD-based tests to identify genomic regions that have undergone 
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selective sweeps. For this haplotype-based test for selection, we focused on the subset of monoclonal P. 
vivax isolates (n=28) and the CP2 P. falciparum group (n=18), which are predominantly monoclonal 
(15/18). 
For P. vivax, we performed the nSL test for positive selection, which represented 45,701 SNPs 
(Figure 4.7). Strikingly, among the strongest 15 strongest signals of positive selection, five were in close 
proximity to potential regulators of gene expression (three AP2-domain containing transcription factors 
and two SET-domain containing proteins, which are histone modulators). Among these 15 regions, four 
were neighboring transporters (MDR1, MDR2, MRP1, and an ABC-transporter) (Table 4.4). Notably, a 
previous comparison of a 1990s-era Peruvian P. vivax isolate to the reference Sal1 strain found an 
increased dN/dS signal at AP2-containing transcription factors and at pvmrp1 [248]. In fact, the strongest 
selective sweep among the P. vivax isolates was on chromosome 14, adjacent to an AP2-domain 
containing transcription factor (PVX_122680). To determine the extent of haplotype homozygosity (i.e. 
how big is the sweep in terms of genomic coordinates), we turned to the extended haplotype 
homozygosity test (EHH). The focal SNP in this region of increased nSL score was used for EHH 
analysis. We identified a 100 kb region of strong linkage disequilibrium around the principle chromosome 
14 locus (Figure 4.8) in isolates with the selected allele. In addition to the AP2-domain transcription 
factor, this region contained 25 genes (Table 4.5). Analysis of the entire Plasmodium vivax population 
using nSL yielded qualitatively similar results (Figure 4.9). Furthermore, the iHS statistic - which has 
been used extensively in malaria studies - was calculated for these same loci, yielding similar results 
(Figure 4.9). 
Another prominent sweep encompassed the pvmdr1 locus. We explored whether this locus has 
been responsible for a recent sweep. We compared key drug-resistance SNP frequencies in pvmdr1 to 
frequencies in Cambodian isolates collected several years earlier from Kampot province, from 2006-2007 
[249]. Two key mutations (Y976F and F1076L) existed at roughly the same frequency (89% previously 
vs 77% more recently; 87% vs 90%, respectively). This high similarity in allele frequency from samples 
collected before and during the global plan to contain artemisinin resistance provides evidence that the 
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sweep encompassing the pvmdr1 locus was likely not driven by ACT-resistance containment efforts, and 
may be the result of CQ pressure (similar to pfmdr1 mutations in P. falciparum). Similar to another study, 
we did not find any evidence of copy number variations encompassing the pvmdr1 locus [249]. 
A similar analysis of selective sweeps was performed for the 5,158 SNPs of the P. falciparum 
CP2 founder population. Both nSL and iHS statistics revealed a single locus under strong directional 
selection. Surprisingly, this region was near the pfama1 gene (< 20 kb) (which also was the 15th highest 
signal in P. vivax). Previous genome scans have identified this locus as one under a strong selective 
sweep [250,251]. This finding could be due to an incomplete sweep at this locus. To more closely 
investigate the selective forces acting on pfama1, we looked at Tajima’s D for this locus. Gene-wide 
estimate of Tajima’s D was approximately 0.3, indicating that pfama1 is not under extreme balancing 
selection in genome-wide comparisons of Tajima’s D. 
4.3.6 Copy Number analysis 
Segmental duplications (also known as copy-number variants, or CNVs) can drive the evolution 
of parasite populations [252]. To identify CNVs in these genome data, we used a probabilistic framework 
for detecting variants that incorporates multiple types of evidence, as well as a custom search algorithm 
that accommodates the high AT content of Plasmodium species. First, to validate our CNV-calling 
approach, we performed qPCR on 54 of the whole-genome sequenced P. falciparum isolates to determine 
copy-number at pfmdr1 - a known CNV locus in Cambodia. We identified seven isolates with a 
segmental duplication encompassing this locus. In comparison with experimental results, we found that 
both genome-wide CNV-detection methods identified five of these seven isolates, and detected no false 
positives, demonstrating reasonable sensitivity and good specificity. 
When all P. falciparum samples were analyzed, 14 isolates had detectable pfmdr1 duplications, 
including five with 3 copies and two with 4 copies. Beyond pfmdr1, we identified three additional loci 
with CNVs in P. falciparum: the plasmepsin II locus (chromosome 14), rh2b & rh2a (chromosome 13), 
and rab2 (chromosome 8). For plasmepsin II, 40 samples contained a duplication event, including 16 
samples with three copies. We identified two unique segmental duplications that encompassed the rh2b 
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and rh2a loci. One event spanned both genes (n=8) while some samples contained only an rh2b 
duplication. Finally, a large duplication event spanned the rab2 locus (ras-related protein Rab-2) in a 
single isolate. This duplication also encompassed PF3D7_1230800 (unknown function), PF3D7_1230900 
(serine/threonine protein kinase RIO1), PF3D7_1231000 (unknown function), PF3D7_1231200 
(unknown function), PF3D7_1231300 (unknown function), and PF3D7_1231400 (amino acid 
transporter). Similar to the most comprehensive P. falciparum CNV analysis to date [252], we found no 
evidence of selective sweeps around CNVs. 
We identified a limited number of copy-number variants in the P. vivax genomes. The following 
genes were found to have several copies. Sixteen Cambodian P. vivax had a 2x duplication encompassing 
the Duffy binding protein (dbp, PVX_110810), which was previously described [253] in P. vivax isolates 
worldwide. We also discovered one P. vivax isolate which contained 4x pvdbp duplication event. 
Additionally, we identified 13 P. vivax isolates with a deletion that includes the two 5’-most exons of the 
cytoadherence-linked asexual protein (clag, PVX_094265) deletion, as well as an exported protein of 
unknown function (PVX_094270). Deletions of clag are common in P. falciparum cultured strains [254]. 
Similar to P. falciparum, there was no evidence of selective sweeps that encompassed segmental 
duplications in the P. vivax genome. In addition, similar to another study, we did not find any evidence of 
copy number variations encompassing the pvmdr1 locus [249]. 
4.3.7 Genome scans for balancing selection 
Genome-wide scans for balancing selection have been instrumental in identifying factors that 
shape populations. For P. falciparum populations, scans for balancing selection have contributed greatly 
to our understanding of the breadth of host-parasite antigen-antibody interactions. This dataset affords us 
the unique opportunity to investigate the signatures of balancing selection in co-endemic P. vivax and P. 
falciparum populations. We calculated Tajima’s D for every non-excluded gene in the P. vivax and P. 
falciparum genome (approximately 5,300 and 5,200 genes, respectively), and observed, in both species, 
mean value D < 0, with a strong right skew (Figure 4.10). Because Tajima’s D is sensitive to 
demographic history, we used the best-fit demographic models - as determined above - to parameterize 
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coalescent simulations on a gene-by-gene basis. The results of these simulations suggested that the 
Tajima’s D distribution we observed largely reflects the population expansion that both P. vivax and P. 
falciparum have undergone (data not shown). 
4.3.8 Ortholog analyses 
Studying whole-genomes from sympatric P. vivax and P. falciparum populations allows us to 
investigate the congruity of selective forces acting on orthologs. A realistic explanation for the 
mechanisms of population resilience underlying the dramatic differences we observe in P. vivax and P. 
falciparum could be asymmetric treatment and responses of orthologs. For example, one likely scenario 
for explaining the differences between P. falciparum and P. vivax is that there have been particular 
genetic loci in P. falciparum that are subjected to strong selective pressures, when orthologous genes 
from P. vivax have not been exposed to such pressures. 
There are 1,852 genes that have a single P. vivax / P. falciparum ortholog [255]. For each 
orthologous pair, we studied selection dynamics to identify both concordant and discordant ortholog 
pairs. As above, we calculated Tajima’s D for each gene with an ortholog from P. vivax and P. falciparum 
and also performed a per-exon analysis (data not shown). We also investigated a new concept, the idea of 
𝚫Tajima’s D, to study the genes with discordant signatures of selection. Overall, the signature of selection 
was concordant between orthologs (values near 0), though there were a subset ortholog pairs with extreme 
negative or extreme positive 𝚫Tajima’s D (Figure 4.11). We investigated the top 1% of orthologous gene 
pairs with opposing signals of selection by GO-term analysis, but found no enrichment. It is possible that 
the tails of the 𝚫Tajima’s D distribution hold meaningful biological signals, but that any signal is 
obscured by the high proportion of genes with unknown function in the tails of this distribution. 
4.4 Discussion 
4.4.1 Species-specific mechanisms of population-level resilience 
In this study, we whole-genome sequenced 70 P. vivax and 80 co-endemic P. falciparum clinical 
isolates from three sites in western Cambodia. This dataset represents a unique resource for comparing the 
effects of selective forces have had on the genomes of  these Plasmodium species. Because these isolates 
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were collected during a concerted malaria-elimination campaign, they can shed light on the different 
responses of these two species to control efforts. We applied population-genetic methods to investigate 
these responses. 
On the basis of epidemiological data, it has been observed that P. vivax may be more difficult to 
eliminate than P. falciparum [8]. However, it is as-yet unclear why this may be the case. Understanding 
the long-term and recent demographic histories, as well as comparing the respective population structures, 
of Cambodian P. vivax and P. falciparum may be of great utility to malaria control programs by shedding 
light on how the population has responded to interventions and documenting how the genome has 
changed due the imposed selection. Sympatric whole-genome data for P. vivax and P. falciparum are 
particularly suited for such an investigation. Similar to several recent studies of co-endemic P. falciparum 
and P. vivax isolates [256–261], we observed more genetic structuring among P. falciparum isolates, 
which were split among four highly separated populations, than among P. vivax. Our results add the first 
whole-genome evidence to the increasingly common observation that P. vivax is typically has a simpler, 
less fractured population structure more admixed than sympatric P. falciparum, even in the face of large 
bed-net distributions and intensive diagnosis and treatment. The demographic models support the 
population structure analysis as well. Given our sample sizes, we have power for robust detection of 
ancient demographic events, and potentially power for detection of recent events [262]. Best-fit 
demographic models indicated that P. vivax has undergone steady exponential growth in the region with 
genetic diversity within the P. vivax population has expanding more rapidly compared the admixed 
founder population CP2. Consistent with this, a demography-adjusted estimate of the population mutation 
rate (θ) - a proxy for effective population size (Neff) - found that the P. vivax Neff is substantially larger 
than P. falciparum. The overall population demographic history encompassing all isolates is best 
described by an exponential growth model, consistent with population splits and expansion of what 
appear to be clonal lines of drug resistant parasites (Parobek et al., in submission). 
These demographic scenarios match epidemiological observations in the region [8]. Specifically, 
even as P. falciparum cases have dropped rapidly, P. vivax cases have increased. This could be due to (1) 
78 
the ability of P. vivax infections to go dormant or undetected during hypnozygony, allowing the 
population to maintain occult genetic diversity, (2) earlier transmission of P. vivax due to earlier 
gametocytemia, allowing transmission events to occur prior to clinical symptoms and presentation for 
treatment, or (3) a release of P. vivax competitive inhibition due to falling P. falciparum cases [263,264]. 
It could also be because P. vivax has unique genetic mechanisms to maintain its resilience in spite of 
control measures. If there are different mechanisms between P. vivax and P. falciparum, these differences 
might be seen in scans for selection. 
These data enabled direct comparison of selective signatures in P. vivax and P. falciparum 
orthologs. While it is known that orthologs operate under different selective regimes [244], the ability to 
simultaneously investigate thousands of orthologs presents a rich resource for generating hypotheses 
about the biological differences between P. vivax and P. falciparum. We used best-fit demographic 
scenarios to construct null distributions of Tajima’s D values for Cambodian P. vivax and P. falciparum. 
Using these distributions, we identified genes in both P. vivax and P. falciparum under extreme 
directional or balancing selection. On a gene-wise basis, both species showed a negative mean Tajima’s D 
value with strong right skew (Figure 4.10), similar to previous reports from Africa in P. falciparum 
[265]. Among the minority of genes with signatures of balancing selection, candidate erythrocytic stage 
vaccine antigens in both species were over-represented. Analysis of 𝚫Tajima’s D between orthologous 
gene pairs revealed a small minority of genes that have highly discordant marks of selection. As loci 
within the P. falciparum and P. vivax genomes receive better annotation, this signal in particular may 
point the way to important biological differences between these two species. 
We also employed haplotypic measures, nSL and iHS, to assess for genomic regions in the 
populations under recent directional selection and to identify incomplete sweeps. To date, P. falciparum 
studies have demonstrated that the strongest signatures of selection are nearby multidrug transporters, 
antimalarial targets, and antigens [250,251,266–268]. Similarly, in P. vivax, we identified some selective 
sweeps with the focal variant occurring in close proximity to known and potential drug-resistance genes 
(pvmdr1, pvmdr2, pvmrp1, and an ABC-family transporter; Table 4.4). 
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However, surprisingly, in our P. vivax population sample, the strongest selective sweeps occurred 
in close proximity to multiple AP2- and SET-domain containing proteins. Both of these classes of 
proteins are likely transcriptional regulators, raising the possibility that P. vivax is responding to selective 
pressures by altering its transcriptional profile. Fully one-third of the strongest signatures of directional 
selection in P. vivax were likely driven by transcriptional regulators. These results suggest that while P. 
falciparum populations experience sweeps of drug-resistance loci among most studies 
[250,266,267,269,270], P. vivax populations may rely more heavily on complex transcriptional 
mechanisms to evade selective pressures. Of note, the statistical tests for directional selection used here 
can not determine the presence of a sweep if a mutation is at fixation. Within our samples, it is clear that 
several drug resistance mutations are nearly fixed within the population, including the CVIET haplotype 
pfcrt associated with chloroquine resistance (Figure 3.11), thus masking these selected areas in our 
analysis. These data suggest that molecular surveillance for mutations in drug-resistance genes may be of 
comparatively limited utility in P. vivax, if indeed transcriptional regulation plays an important role in 
promoting parasite fitness. 
This finding is not, however, not an absolute difference between species. A closer look at 
previously published P. falciparum scans for selection in multiple locations in Africa reveals a striking 
finding. Park et al. found a region on chromosome 6 strongly with strong signal of positive selection in 
pyrimethamine-resistant parasites - this region contained, among other things, a SET-domain containing 
protein (PF3D7_0629700), which was nearly at the center of the selective sweep [270], and this is the 
ortholog of the SET-domain protein on chromosome 11 (PVX_114585). Nwakanma et al. also found this 
region to be under “exceptionally strong” directional selection in the Gambia [271], as have other studies 
[250,266]. Though it is known that transcriptional timing can be an important component of P. 
falciparum drug-resistance responses [43], these results suggest an underappreciation for the role of 
transcriptional regulation modification in P. falciparum fitness. 
Among the CP2 P. falciparum population, we identified only a single locus with a convincing 
signature of directional selection. This relative lack of loci under directional selection could be due to 
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unrecognized multiclonal infections in the CP2 group, leading to haplotype breakdown during sequence 
analysis. It could also be due to undetected fixed sweeps, which nSL and iHS are insensitive to detect. 
Surprisingly, this locus was in close proximity to the pfama1 locus. While past scans for directional 
selection have identified a strong signature at this locus [250,251], it remains unclear whether the pfama1 
locus or a nearby gene is driving this sweep. Because the nSL and iHS statistics are sensitive for 
incomplete sweeps, a strong signature of balancing selection in a subdomain of pfama1 could be causing 
this signature. This finding bears further investigation. 
We also sought to identify and characterize segmental duplications in the P. vivax and P. 
falciparum genomes, and, as our data are uncaptured, they are particularly useful for studies of structural 
variation. Segmental duplications in Plasmodia species can be associated with increased fitness in certain 
settings (eg. the P. falciparum multidrug resistance transporter), and studies of copy-number changes 
have proved instrumental in uncovering unique P. vivax biology [253]. A striking finding was the highly 
duplicated nature of the P. vivax Duffy binding protein (pvdbp) in this Cambodian population. A 
conserved segmental duplication encompassing the pvdbp locus was previously described in a handful of 
globally sourced P. vivax isolates, suggesting a recent duplication event and rapid sweep, perhaps because 
it conferred a RBC-invasion advantage. That the pvdbp duplication is so common in our sample (17/70 
isolates, including a single 4x duplication) suggests an important mechanism that may transcend invasion 
of Duffy-negative human hosts. Similar to a recent study of segmental duplications in the P. falciparum 
genome [43,252], we found no evidence that copy-number events are driving selective sweeps in either P. 
falciparum or P. vivax. 
Our study is subject to some limitations. First, although we have curated our data carefully - 
performing extensive tests to determine the best alignment, filtering, and variant-calling approaches - 
unappreciated error at these steps could spawn spurious variants and skew the allele frequency spectrum. 
The risk of this is heightened in P. vivax, for which extensive recognized and unrecognized paralogous 
families present significant mapping and variant-calling challenges [272]. 
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Second, our demographic inferences are constructed upon Wright-Fisher assumptions. Malaria 
parasites have a complex lifecycle, including stages in human and mosquito, with multiple clonal 
generations occurring within the host bloodstream and frequent bottlenecks during transmission [273]. 
Such realities violate the assumptions of standard population genetic models, and may complicate the 
process of population-genetic inference from genetic data that relies on these models. These peculiarities 
of the malaria lifecycle may skew the allele frequency spectrum toward increased singletons - even at 
neutral sites - leading to quantitatively or even qualitatively inappropriate demographic conclusions 
[268,274]. Even if the models do approximate the  genetic features of Plasmodia, our power to accurately 
infer recent population events from the site-frequency spectrum, may be limited for very recent events 
[262]. Selection bias could further limit our ability to infer population dynamics from our sample, as we 
sequenced parasites (1) causing patent disease, and (2) with a high enough density for whole-genome 
sequencing. 
Third, while P. vivax and P. falciparum populations in western Cambodia have been exposed to 
similar selective pressures over time, these pressures are certainly not identical, especially with respect 
pharmacotherapy. For roughly ten years, from the early 2000s until 2012, national guidelines in 
Cambodia mandated artemisinin-based therapy for P. falciparum infections and chloroquine-based 
therapy for P. vivax [28]. Despite this important difference, P. vivax and P. falciparum populations almost 
certainly experienced cross-treatment, particularly in cases of mixed infections or empiric diagnosis and 
treatment.  
Despite these shortcomings, our study has fundamental strengths. We have a reasonable sample 
size, including the largest P. vivax population sequenced from any single country. Importantly, none of 
these samples were hybrid captured, giving us greater confidence in the quantitative accuracy of calls in 
mixed infections and structural variants. This co-endemic P. vivax and P. falciparum genome-wide 
sequencing dataset is a first, and will continue to provide useful grounds for mining. 
Our findings raise important questions. First, while the total number of P. falciparum cases in 
Cambodia decreased, our demographic models show a slowly increasing Neff - at least for the CP2 
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founder population. Although it is possible that our demographic models are detecting ancient rather than 
recent trends, another study of isolates in this area identified the same trend [275], lending credence to our 
findings and suggesting that recent control efforts have not significantly decreased P. falciparum genetic 
diversity in the region. 
That P. vivax - and to some extent P. falciparum - may modulate transcriptional regulation in 
their response to control efforts is a finding that bears closer investigation. A multi-step approach to 
investigating these findings should be adopted. First, we need to see whether the findings that strong 
selective sweeps near potential transcriptional modulators (in our case, AP2-domain transcription factors 
and SET-domain chromatin modifiers) are replicable in other populations. For example, it would be 
interesting to see whether these signals hold in P. vivax populations from places with prolonged zero-
transmission seasons (eg. North Korea). A strong signal on P. falciparum chromosome 6 centered near a 
SET-domain chromatin modifier has already been identified in multiple studies of African isolates 
[250,266,270,271]. 
Once confirmed, the selected alleles in these sweeps should be studied for their specific role in 
transcriptional regulation. In P. falciparum, in vitro studies could uncover the role of selected alleles in 
transcriptional changes throughout the parasite lifecycle. While culture conditions certainly do not mirror 
field conditions in an elimination setting, such experiments would provide well-controlled and evidence. 
Determining the role of selected P. vivax variants will be more challenging. Modifications to Plasmodium 
knowlesi homologs could be tested in culture [276]; humanized mice could be infected with transgenic P. 
vivax allowing for transcriptional analysis through the liver stage [277,278]; or monkeys could be infected 
with transgenic P. vivax, allowing for transcriptional analysis through the blood stage [279]. If such 
experiments demonstrate that selected variants do indeed modulate transcription, this would provide key 
evidence of an advanced parasitic response to selective pressure. It would also suggest that tracking 
highly fit P. vivax parasites could be complicated, and would provide further evidence in support of the 
idea that P. vivax will be the more challenging species to eliminate. 
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In summary, we have presented evidence that P. vivax and P. falciparum populations in 
Cambodia have responded in substantively different ways to the selective pressure of the artemisinin-
resistance containment campaign. While P. falciparum has seen population splitting with clonal and 
sporadic transmission, the P. vivax population remains admixed, with strong growth genetic diversity 
perhaps enabled by a high frequency of multiple infections. There are clear differences in the genes under 
selection in P. vivax and P. falciparum, with many orthologs under strongly opposite signals of selection. 
Finally, while both P. vivax and P. falciparum experience selective sweeps, the strongest sweeps in P. 
vivax occur nearby transcriptional regulators while, in several previously published P. falciparum 
datasets, the strongest sweeps occur near drug-resistance genes. These findings highlight potentially 
important differences between P. vivax and P. falciparum, suggest that P. vivax will be more difficult to 
eliminate, and indicate that a true understanding of P. vivax biology will require additional studies of this 
parasite. 
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Model 𝜃 
ηD* 
(0.001 - 1.0) 
ηG* 
(1.0 - 100) 
T* 
(0.01 - 5.0) 
Log Likelihood AIC 
Static 1868.499 - - - -911.145 1824.29 
NegG 5260.287 0.328 - 4.583 -1007.829 2021.65 
PosG-Epoch 898.556 - 9.819 0.672 -28.569 63.138 
PosG-Exp 850.687 - 19.999 1.032 -28.077 62.154 
BG 4053.125 0.0307 4.0639 0.367 -28.020 64.04 
 
Table 4.1 Demographic history of P. vivax monoclonals. 
Highest log-likelihood parameter sets were selected from 100 model-fit replicates. * Ranges explored for 
optimization are provided for optimizable parameters. 
 
Model 𝜃 
ηD* 
(0.001 - 1.0) 
ηG* 
(1.0 - 100) 
T* 
(0.01 - 5.0) 
Log Likelihood AIC 
Static 1568.496 - - - -601.569 1205.14 
NegG 1406454 0.00111 - 4.755 -602.773 1211.546 
PosG-Epoch 848.495 - 7.798 0.547 -31.500 79.00 
PosG-Exp 816.378 - 14.342 0.830 -27.594 61.188 
BG 816.373 0.972 14.332 0.839 -27.593 63.186 
 
Table 4.2 Demographic history of P. vivax entire population 
Highest log-likelihood parameter sets were selected from 100 model-fit replicates. * Ranges explored for 
optimization are provided for optimizable parameters. 
 
Model 𝜃 
ηD* 
(0.001 - 1.0) 
ηG* 
(1 - 100) 
T* 
(0.01 - 5.0) 
Log Likelihood AIC 
Static 396.184 - - - -27.336 56.672 
NegG 396.228 0.9997 - 0.820 -27.340 68.68 
PosG-Epoch 266.604 - 1.691 1.729 -24.789 55.578 
PosG 240.603 - 1.942 4.994 -24.736 55.472 
BG 304.952 0.998 1.538 2.282 -24.738 57.476 
 
Table 4.3 Demographic history for the core P. falciparum population (CP2). 
Highest log-likelihood parameter sets were selected from 100 model-fit replicates. * Ranges explored for 
optimization are provided for optimizable parameters.  
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Chr 
Focal SNP Stats Sweep Region Stats 
Location nSL Closest Plausible Genetic Driver Gene ID Distance* 
14 797870 6.175 
transcription factor with AP2 domain(s), 
putative (ApiAP2) 
PVX_122680 -4462 
14 1650897 4.386 
heterochromatin protein 1 (HP1);                 
H3 lysine methyltransferase (SET10)   
PVX_123682; 
PVX_123685 
999 
9918 
10 351691 4.207 
multidrug resistance protein 1,                
putative (MDR1) 
PVX_080100 10010 
04 577543 4.201 
serine-repeat antigen 4 (SERA) 
serine-repeat antigen 5 (SERA) 
PVX_003825; 
PVX_003830 
789 
-1691 
02 85446 -3.948 numerous vir and fam members - - 
03 368737 -3.914 hypothetical genes - - 
12 2421187 3.591 multidrug resistance protein 2 (MDR2) PVX_118100 -4361 
13 396427 3.589 
ABC transporter B family member 7, 
putative (ABCB7) 
PVX_084521 -7326 
11 749030 -3.567 SET domain containing protein PVX_114585 46877 
11 1900445 -3.487 
transcription factor with AP2 domain(s), 
putative (ApiAP2) 
PVX_113370 -31184 
06 574362 -3.438 
merozoite TRAP-like protein,                 
putative (MTRAP)   
PVX_111290 6929 
09 1693066 -3.349 
transcription factor with AP2 domain(s), 
putative (AP2-O) 
PVX_092760 7201 
02 145835 3.318 
multidrug resistance-associated protein 1, 
putative (MRP1) 
PVX_097025 7807 
07 934541 3.268 hypothetical genes - - 
09 1252731 3.219 
heat shock protein 70, putative; 
apical membrane antigen 1 (AMA1) 
PVX_092310 
PVX_092275 
5’UTR 
-21528 
 
Table 4.4 Top fifteen P. vivax genomic regions under recent directional selection. 
nSL analysis was performed in P. vivax monoclonal infections to avoid false haplotype breakdown in 
multiclonal clinical isolates. * Distance from focal SNP to potential driver gene;                                                   
a negative sign indicates upstream. 
 
  
86 
Gene ID Gene Description Position 
PVX_122645 
pre-mRNA-processing factor 40, putative 
(PRP40) 
Pv_Sal1_chr14: 745,554 - 749,056 (+) 
PVX_122650 choline-phosphate cytidylyltransferase, putative Pv_Sal1_chr14: 752,305 - 755,482 (+) 
PVX_122655 hypothetical protein, conserved Pv_Sal1_chr14: 756,864 - 759,127 (+) 
PVX_122660 protein transport protein SEC20, putative Pv_Sal1_chr14: 759,434 - 761,371 (-) 
PVX_122665 hypothetical protein, conserved Pv_Sal1_chr14: 762,592 - 765,741 (-) 
PVX_122670 
U4/U6.U5 tri-snRNP-associated protein 2, 
putative 
Pv_Sal1_chr14: 768,843 - 770,900 (+) 
PVX_122675 DNA replication licensing factor MCM4, putative Pv_Sal1_chr14: 772,315 - 775,182 (+) 
PVX_122680 
transcription factor with AP2 domain(s), putative 
(ApiAP2) 
Pv_Sal1_chr14: 785,708 - 793,408 (+) 
PVX_122685 hypothetical protein, conserved Pv_Sal1_chr14: 794,062 - 796,623 (-) 
PVX_122690 hypothetical protein, conserved Pv_Sal1_chr14: 797,092 - 798,234 (+) 
PVX_122695 hypothetical protein, conserved Pv_Sal1_chr14: 799,176 - 799,918 (-) 
PVX_122700 hypothetical protein, conserved Pv_Sal1_chr14: 800,245 - 802,852 (+) 
PVX_122705 hypothetical protein, conserved Pv_Sal1_chr14: 803,430 - 803,912 (-) 
PVX_122710 40S ribosomal protein S19, putative (RPS19) Pv_Sal1_chr14: 805,253 - 806,554 (+) 
PVX_122715 hypothetical protein, conserved Pv_Sal1_chr14: 807,324 - 809,996 (-) 
PVX_122720 hypothetical protein, conserved Pv_Sal1_chr14: 811,474 - 812,043 (-) 
PVX_122725 ferredoxin, putative Pv_Sal1_chr14: 814,528 - 815,735 (-) 
PVX_122730 
glycerol-3-phosphate 1-O-acyltransferase, 
putative (G3PAT) 
Pv_Sal1_chr14: 816,300 - 817,556 (+) 
PVX_122735 hypothetical protein, conserved Pv_Sal1_chr14: 819,451 - 824,001 (+) 
PVX_122740 structural maintenance of chromosome 2, putative Pv_Sal1_chr14: 824,711 - 829,052 (-) 
PVX_122742 conserved Plasmodium protein, unknown function Pv_Sal1_chr14: 830,213 - 832,084 (+) 
PVX_122745 hypothetical protein, conserved Pv_Sal1_chr14: 832,095 - 834,081 (+) 
PVX_122750 hypothetical protein, conserved Pv_Sal1_chr14: 834,505 - 836,979 (-) 
PVX_122755 translocation protein SEC63, putative (SEC63) Pv_Sal1_chr14: 839,917 - 842,636 (-) 
PVX_122760 hypothetical protein, conserved Pv_Sal1_chr14: 844,891 - 846,828 (+) 
 
Table 4.5 Loci falling within the principal P. vivax selective sweep, occurring on chromosome 14. 
Identifier, description, and location of genes that occur within the sweep are provided.                                  
While the sweep haplotype extends approximately 50 Kb in each direction,                                                                                   
genes occurring within 5 Kb of the focal SNP are highlighted. 
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Species Province SRA Accession Numbers 
P. vivax Battambang SRR2315729, SRR2315849, SRR2316038, SRR2316105, SRR2316478, 
SRR2316872, SRR2316895, SRR2317109, SRR2317489 
P. vivax Kampot SRR2317560, SRR2315958, SRR2315988, SRR2316010, SRR2316011, 
SRR2316013, SRR2316015, SRR2316017, SRR2316032 
P. vivax Oddar 
Meanchey 
SRR2316034, SRR2316036, SRR2316041, SRR2316044, SRR2316048, 
SRR2316051, SRR2316083, SRR2316087, SRR2316091, SRR2316095, 
SRR2316098, SRR2316101, SRR2316108, SRR2316111, SRR2316115, 
SRR2316117, SRR2316172, SRR2316252, SRR2316299, SRR2316344, 
SRR2316398, SRR2316422, SRR2316531, SRR2316564, SRR2316625, 
SRR2316658, SRR2316724, SRR2316755, SRR2316807, SRR2316839, 
SRR2316865, SRR2316867, SRR2316875, SRR2316879, SRR2316883, 
SRR2316887, SRR2316889, SRR2316890, SRR2316891, SRR2316892, 
SRR2316893, SRR2316894, SRR2316920, SRR2316921, SRR2316922, 
SRR2316923, SRR2316924, SRR2316925, SRR2316926, SRR2316970, 
SRR2317000, SRR2317001, SRR2317142, SRR2317171, SRR2317223, 
SRR2317268, SRR2317321, SRR2317322, SRR2317410, SRR2317444 
P. 
falciparum 
Battambang SRR2317584, SRR2317585, SRR2317700, SRR2317711, SRR2317722, 
SRR2318021, SRR2318061, SRR2318484, SRR2318682, SRR2318694 
P. 
falciparum 
Kampot SRR2317586, SRR2317587, SRR2317692, SRR2317693, SRR2317694, 
SRR2317695, SRR2317696, SRR2317697, SRR2317698 
P. 
falciparum 
Oddar 
Meanchey 
SRR2317699, SRR2317701, SRR2317702, SRR2317703, SRR2317704, 
SRR2317705, SRR2317706, SRR2317707, SRR2317708, SRR2317709, 
SRR2317710, SRR2317712, SRR2317713, SRR2317714, SRR2317715, 
SRR2317716, SRR2317717, SRR2317718, SRR2317719, SRR2317720, 
SRR2317721, SRR2317723, SRR2317724, SRR2317725, SRR2317726, 
SRR2317727, SRR2317728, SRR2317729, SRR2317730, SRR2318019, 
SRR2318020, SRR2318023, SRR2318024, SRR2318031, SRR2318033, 
SRR2318034, SRR2318035, SRR2318039, SRR2318040, SRR2318041, 
SRR2318056, SRR2318126, SRR2318130, SRR2318177, SRR2318219, 
SRR2318297, SRR2318319, SRR2318368, SRR2318415, SRR2318446, 
SRR2318479, SRR2318576, SRR2318622, SRR2318670, SRR2318675, 
SRR2318676, SRR2318677, SRR2318678, SRR2318679, SRR2318680, 
SRR2318681, SRR2318683, SRR2318684, SRR2318685, SRR2318686, 
SRR2318688, SRR2318689, SRR2318690, SRR2318691, SRR2318692, 
SRR2318693, SRR2318702, SRR2318703, SRR2318704 
 
Table 4.6 Sequence Read Archive accession numbers for P. vivax and P. falciparum isolates whole-
genome sequenced in this study. 
Accessions are classified according to species (P. vivax or P. falciparum) and province of collection 
(Battambang, Kampot, or Oddar Meanchey). 
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Figure 4.1 Multiplicity of infection for P. vivax and P. falciparum. 
(A) FWS calculated for P. vivax and P. falciparum. Points represent point estimate of FWS for each sample 
in the respective population. Vertical bars represent the maximum and minimum value in 1000 bootstrap 
replicates, which downsampled the number of variants to be equal for P. vivax and P. falciparum, to 
correct for the increased number of P. vivax variants. (B) Summary bargraph representing the number of 
P. vivax and P. falciparum clinical isolates considered monoclonal or polyclonal,                                         
based on a cutoff of FWS < 0.95 being considered polyclonal. 
  
89 
 
Figure 4.2 Principal components analysis of P. vivax and P. falciparum populations from Cambodia. 
Calculated from genetic distance matrices which were calculated from single-nucleotide variant data from 
whole-genome sequencing data for each of 70 P. vivax clinical isolates (A) and 80 P. falciparum clinical 
isolates (B). Noise was added to allow visualization of isolates. 
  
90 
 
Figure 4.3 K-means clustering provides evidence for the number of subpopulations in                                  
P. vivax and P. falciparum populations. 
Nonparametric k-means clustering of total genetic diversity in P. vivax and P. falciparum isolates. For P. 
vivax, clustering suggests that all parasites are drawn from the same population. For P. falciparum, 
Increasing the number of clusters from n=3 to n=4 yields a substantial improvement in Bayesian 
information criterion (BIC). While subsequent increases do yield BIC improvements, the improvement in 
goodness of fit is not commensurate with the cost associated with increased degrees of freedom. 
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Figure 4.4 Allele-frequency spectra suggest strong, sustained growth for the P. vivax population, 
but muted population expansion for P. falciparum. 
We observed a preponderance of low-frequency alleles in the P. vivax population. Under a Wright-Fisher 
model of genetic evolution, this suggests that the P. vivax population has undergone a recent expansion. 
In contrast, for P. falciparum, we observed an excess in intermediate-frequency minor alleles,                  
reflecting the subdivided population structure. 
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Figure 4.5 Allele-frequency spectra for P. falciparum CP2 founder population and                                      
P. vivax monoclonal isolates. 
When considered in isolation, there is no increase in intermediate-frequency alleles within the P. 
falciparum CP2 founder population. Similar to the entire P. vivax population, the P. vivax monoclonal 
isolates have a strong overrepresentation of low-frequency alleles,                                                          
suggesting an expanding population size. 
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Figure 4.6 Five one-population models were used for demographic inference. 
The following models were fitted to observed P. vivax and P. falciparum allele frequency spectra under 
using a diffusion approximation to population evolution: (A) a model of no change in effective population 
size through time; (B) a model of population decline beginning at time T; (C) A model of exponential 
population expansion, beginning at time T; (D) a two-epoch model of sudden population expansion at 
time T; (E) a model of rapid population decline followed by exponential growth, beginning at time T. 
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Figure 4.7 Haplotype sweep provides evidence of positive selection in Cambodian P. vivax. 
Manhattan plot of normalized nSL values is shown. Each point corresponds to a SNP, and the top 0.5% of 
hits are colored in red. This view suggests that there are several genomic regions under positive selection, 
including areas near transcription factors (AP2-containing domain), chromatin regulators (SET10, HP1), 
antigens under known positive selection (SERA4 & 5), and drug resistance genes (MDR1). 
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Figure 4.8 Evidence of recent positive selection centered around an AP2-domain containing 
transcription factor. 
The upper panel shows the decay of extended haplotype homozygosity (EHH) for the selected (orange) 
and unselected (blue) haplotypes. It is evident that a large region surrounding the selected focal variant is 
in strong linkage disequilibrium. The lower panel shows a haplotype bifurcation diagram centered on the 
focal SNP. Haplotypes extend approximately 50 Kb in either direction from the center SNP.                
Haplotype frequency correlates with line thickness. 
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Figure 4.9 Additional haplotype-based scans for directional selection in P. vivax. 
The upper panel depicts results of nSL analysis for the entire P. vivax sample. As many P. vivax infections 
have a high multiplicity of infection, haplotype-based test results are muted. Nevertheless, many of the 
same loci as in the monoclonal analysis are identified. The lower panel depicts results of iHS analysis 
applied to the P. vivax monoclonal samples. The strongest signal matches that in the nSL monoclonal 
analysis, with the focal variant occurring in close proximity to an AP2-domain transcription factor. 
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Figure 4.10 Distributions of P. vivax and P. falciparum gene-wise Tajima’s D values. 
Tajima’s D was calculated for each gene in the entire P. vivax and P. falciparum population set. Both 
distributions have a median value D < 0, and a strong right skew. The negative median values may reflect 
the history of population expansion. The strong right skew is likely driven by a small subset of genes 
under strong balancing selection. In the distribution of P. falciparum values, there is a strong 
overrepresentation of D values in the range from 0.0 to 2.0. This is due to “balanced” allele frequencies at 
many loci caused multiple discrete subpopulations. 
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Figure 4.11 Comparison of Tajima’s D values between P. vivax and P. falciparum orthologs. 
For the 1852 P. falciparum and P. vivax genes with a single cross-species ortholog, the difference in 
Tajima’s D value was calculated to identify ortholog pairs with discordant signatures of selection.         
The top 1% of orthologous gene pairs with opposing signals are highlighted. 
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CHAPTER 5: DISCUSSION AND FUTURE DIRECTIONS 
5.1 Principal Findings 
P. vivax and P. falciparum are pathogens with many genetic mysteries yet to solve. Through these 
studies, we have provided compelling evidence regarding the population-level genetic similarities and 
differences between these two Plasmodia species. In our first study, we deep sequenced the (major 
surface antigen 1) pvmsp1 and (circumsporozoite protein) pvcsp genes from Cambodian clinical isolates 
[280]. We compared the genetic diversity in Cambodian pvmsp1 and pvcsp sequence sets with previously 
published pvmsp1 and pvcsp sequence sets from around the world, finding markedly different patterns of 
geospatial genetic diversity at these loci. Notably, pvcsp sequences clustered continent - or even country - 
while pvmsp1 sequences from around the world were intermixed, similar to a previous study of another 
blood-stage antigen, pvama1 [145]. Not only do these patterns reflect the differing biology and selective 
pressures that shape these loci, but they also highlight the need for thoughtful marker selection and for 
caution when drawing conclusions about population structure and differentiation from genetic markers. In 
this study, we identified a region of dramatically elevated genetic diversity in pvmsp1, and have used this 
region as a tool in several studies ([56] and unpublished). Finally, orthologous CSP domains are under 
opposite patterns of selection in P. vivax and P. falciparum [140], demonstrating that a true understanding 
of P. vivax biology cannot be inferred from P. falciparum, but rather will require P. vivax-specific 
investigation. 
In our second study, we whole-genome sequenced nearly 80 P. falciparum clinical isolates from 
Cambodia and compared patterns of genetic diversity with patterns of measured ACT partner-drug 
resistance. We found that the Cambodian P. falciparum population is fractured into at least four 
subpopulations, which have different artemisinin and partner-drug resistance profiles. We found that ACT 
partner-drug resistance to piperaquine and mefloquine have arisen on different genetic backgrounds. We 
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also found that infections with parasites of one rapidly expanding near-clonal subpopulations of P. 
falciparum (CP4) have a much higher treatment-failure rate than infections with parasites from other 
subpopulations. These observations may have implications for malaria treatment policy in Cambodia. We 
have provided a genetic explanation for the observation that DHA-PPQ treatment failures can be treated 
successfully with AS-MQ [28]. In the short-term, triple-artemisinin therapy (TACT) that incorporates an 
artemisinin derivative, PPQ, and MQ may be advisable, and such studies are now underway [281]. In the 
long-term however, TACTs may hasten the onset of even more multidrug-resistant malaria. Ultimately, 
short of malaria elimination or an effective vaccine, novel antimalarials that are introduced as carefully 
controlled combination therapies will be the best solution for malaria drug-resistance. 
In our third study, we compared these Cambodian P. falciparum clinical isolates to sympatric P. 
vivax clinical isolates. It was previously known that P. falciparum cases are declining in Cambodia, even 
as P. vivax cases are increasing [8]. We found genetic evidence in support of these epidemiological 
observations: P. vivax had a higher effective population size and was more admixed compared to P. 
falciparum, suggesting stronger, more sustained transmission. We also found that P. falciparum and P. 
vivax seem to have different response mechanisms to selective pressures. While both P. falciparum and P. 
vivax has responded with copy-number duplications or mutations in drug-resistance genes, the P. vivax 
population has seen several selective sweeps near transcriptional regulators - transcription factors (with an 
AP2 domain) and chromatin modifiers (with a SET domain). Thus, while both species rely on simple 
“drug-resistance variations,” P. vivax may alter its gene-expression profile, though it is currently unclear 
which transcripts are affected. 
In conclusion, these three studies reveal dramatic differences in P. vivax and P. falciparum at 
multiple levels (transcriptional, population structure, response to interventions, selection at antigens). 
They support the conclusions that P. vivax may be more difficult to eliminate than P. falciparum and that 
effective P. vivax control will require tailored interventions. 
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5.2 Primary Limitations and Strengths 
A primary limitation of this work is that it has been observational. While these data are raw 
material for many hypotheses, drawing causal links between observed genetic signatures and biological 
processes is tenuous at best. In vitro experiments to test our hypotheses and further explore our 
conclusions are needed. An elegant example of how population genetics and molecular epidemiology can 
direct laboratory experiments is seen in the recent discovery of P. falciparum kelch K13-domain 
mutations. Ariey et al. demonstrated - primarily observationally - that specific mutations in this domain 
are associated with increased artemisinin resistance [39]. However, to confirm these conclusions, classical 
transgenic in vitro experiments were needed. The following year, a separate group provided such 
evidence by engineering K13-domain mutations into and out of P. falciparum laboratory strains, and 
observing the expected changes in artemisinin-resistance profiles [40]. Our work thus far has generated 
many hypotheses regarding organismal differences between P. vivax and P. falciparum biology, but 
rigorous experimental confirmation is necessary. 
The entirety of our work has been performed using Cambodian clinical malaria cases. This has 
afforded us a detailed view into the population genetics of Plasmodia in Cambodia. Of the 106 nations 
with active malaria transmission [1], Cambodia may host the most fascinating malaria genetics, due to 
both the in situ emergence of artemisinin resistance (and resistance to most other antimalarials) and a 
recent history of intense malaria control interventions. It seems likely that the recently colorful genetic 
history of Cambodian Plasmodia may limit the generalizability of our findings. However, time after time 
we see reported in the literature the same broad population-level trends we have observed in Cambodia - 
specifically that, suggesting that our findings may have a degree of generalizability [282–287]. These 
reports describe how, global co-endemic P. falciparum populations tend to be clonal with episodic 
transmission and structure-by-geography, while P. vivax populations enjoy a higher effective population 
size, more stable transmission, and increased gene flow between geographic islands.  
A limitation for our work - and for the broader field of malaria genetics - is the lack of 
appropriate models for Plasmodium genetic variation [288]. While most tools for demographic inference 
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or modeling make Wright-Fisher assumptions, free-living Plasmodium populations clearly violate these 
assumptions, especially with respect to non-overlapping generations and a finite, constant population size. 
For example, it is unclear how to take a Plasmodium spp. census - does one estimate population size 
when parasite numbers are increasing in log-linear fashion during the blood stage? Or during the 
bottleneck that occurs through host-to-vector (or vector-to-host) transmission? Or during the within-
vector meiotic stage? While more appropriate models are being developed [289], the field is at present 
left without a satisfactory tool. Genetic models have been important for our work - from estimating the 
significance of observed Tajima’s D values using coalescent simulations [280] to drawing inferences 
regarding the demographic history of P. falciparum and P. vivax. The fact that the models we have used 
may not appropriately describe Plasmodia biology could compromise the quantitative or qualitative 
integrity of our conclusions. 
Despite these limitations, our work represents a significant advance for the field of malaria genetics. In 
collaboration with co-authors from our first publication (see [280]), we have led the field in developing a 
framework for generating, analyzing, and interpreting malaria antigen deep-sequencing data. We have 
also contributed crucial data regarding how P. falciparum population structure interfaces with ACT 
partner-drug resistance. Finally, in undertaking the first genome-by-population study of co-endemic P. 
vivax and P. falciparum, we now have solid hypotheses for how these species differ in their responses to 
malaria control and elimination efforts, and these results will provide a compass for future studies. 
5.3 Unanswered Questions and Future Directions 
Our studies beg additional investigation. Regarding ACT partner-drug resistance among 
Cambodian P. falciparum, there are still many unknowns. It is unclear whether mefloquine (MQ) and 
piperaquine (PPQ) resistance are antagonistic to one another, or whether they have - by chance - occurred 
on different genetic backgrounds. The roughly inverse correlation between MQ and PPQ IC50s that we 
observed raises the possibility that antagonism exists; however, occasional parasites with elevated MQ 
and PPQ IC50s suggest otherwise. Previous studies have demonstrated antagonism between PPQ and MQ 
in vitro [290], but it is unclear whether this translates into resistance antagonism. Additional population 
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studies could shed light. If PPQ and MQ resistance are antagonistic, one would expect the maintenance of 
these distinct population subgroups, with contrasting ACT partner-drug resistance profiles. In vitro and 
clinical surveillance studies could also increase our understanding. If an antagonistic relationship does 
exist, in vitro studies will be necessary to define the molecular nature of this relationship. 
We have also presented the first genome-by-population study of co-endemic P. falciparum and P. 
vivax. A surprising discovery was the stark differences in the types of genes driving selective sweeps in P. 
falciparum and P. vivax malaria. To date, P. falciparum studies have demonstrated that the strongest 
signatures of selection are nearby multidrug transporters, antimalarial targets, and antigens [291–295]. In 
contrast, in our P. vivax population sample, we observed the strongest selective sweeps in close proximity 
to multiple AP2- and SET-domain containing proteins. Both of these classes of proteins are likely 
transcriptional regulators, raising the possibility that P. vivax is responding to selective pressures by 
altering its transcriptional profile. 
 Transcriptional regulation by pathogens in response to sustained drug pressure has been observed 
in fungal pathogens [296]. In our P. vivax population, it is crucial to first identify the selected allele at 
these AP2-domain and SET-domain loci, then to determine their transcriptional effects. RNA-Seq and 
ChIP-Seq experiments may demonstrate that these alleles affect transcription of drug-resistance 
transporters, or they may hint at an undescribed mechanism. Absent a reliable P. vivax culture system, 
these studies may be pursued in P. knowlesi culture [297]. We already have some familiarity with these 
studies. Unpublished work with a collaborator has shown that mutations in the AP2 DNA-binding domain 
of a P. falciparum transcription factor are associated with escape from antibody pressure. Work is 
ongoing to determine whether these mutations affect transcriptional patterns. Short of performing these 
difficult experiments in P. vivax or P. knowlesi culture, we could search for cis-acting regulatory elements 
that may be targets of AP2-binding domain transcription factors, to at least determine which genes might 
be influenced by these alleles. 
In fungal eukaryotic pathogens, sustained drug pressure can also cause chromosomal 
rearrangements, which in turn drive gene expression patterns [296]. It would be interesting to explore P. 
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vivax structural rearrangements as a compensatory mechanism for drug pressure. With our whole-genome 
sequencing data for both P. falciparum and P. vivax, we have an opportunity to perform the first genome-
wide investigation of structural variants in these parasites. Our data may be especially useful for such 
studies because - in contrast to many population-level genome sequencing projects - our isolates were 
sequenced directly, rather than being subject to capture. A preliminary look has revealed some large and 
unexpected structural rearrangements in P. vivax isolates. As more genome-wide data become available 
for both P. vivax and P. falciparum, these questions will be answered in a systematic way. 
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